17 May 2021
EMA/CHMP/276743/2021
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Agenda for the meeting on 17-20 May 2021

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

17 May 2021, 09:00 – 19:30, virtual meeting/ room 1C

18 May 2021, 08:30 – 19:30, virtual meeting/ room 1C

19 May 2021, 08:30 – 19:30, virtual meeting/ room 1C

20 May 2021, 08:30 – 19:30, virtual meeting/ room 1C

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 17-20 May 2021. See May 2021 CHMP minutes (to be published post June 2021 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 17-20 May 2021

1.3. Adoption of the minutes

CHMP minutes for 19-22 April 2021

Minutes from PRocedural and Organisational Matters (PROM) meeting held on 10 May 2021

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. eflornithine / sulindac - Orphan - EMEA/H/C/005043

treatment of adults patients with familial adenomatous polyposis (FAP)

Scope: Oral explanation

Action: Oral explanation to be held on 19 May 2021 at 15:30

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 15.10.2020.

2.1.2. pitolisant - EMEA/H/C/005117

Treatment of Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnoea (OSA)

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 18 May 2021 at 11:00

List of Outstanding Issues adopted on 22.04.2021, 25.03.2021, 10.12.2020. List of Questions adopted on 25.06.2020.

2.1.3. tanezumab - EMEA/H/C/005189

treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate

Scope: Oral explanation

Action: Oral explanation to be held on 18 May 2021 at 16:00

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 23.07.2020.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0097

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults for Keytruda, based on the results from the pivotal KEYNOTE-590 (KN590) trial. Phase 3, randomized, double-blind, placebo-controlled, multisite study to evaluate the efficacy and safety of pembrolizumab in combination with chemotherapy (cisplatin and 5-FU) versus chemotherapy (cisplatin with 5-FU) as first-line treatment in participants with locally advanced unresectable metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction; as a consequence sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version of the RMP (Version 30.1) has also been submitted."

Action: Possible oral explanation to be held on 18 May 2021 at 14:00

Request for Supplementary Information adopted on 22.04.2021, 25.02.2021.

See 5.1

2.3.2. Veklury – remdesivir - EMEA/H/C/005622/R/0015

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson

Scope: Renewal of conditional marketing authorisation, possible oral explanation

Action: Possible oral explanation to be held on 17 May 2021 at 16:00

The RSI adopted in March was revised at the April plenary following conclusion of the

LEG/31 procedure.

Request for Supplementary Information adopted on 25.03.2021.

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. odevixibat - Orphan - EMEA/H/C/004691

Albireo; treatment of progressive familial intrahepatic cholestasis (PFIC)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 20.04.2021. List of Questions adopted on 23.02.2021.

3.1.2. setmelanotide - Orphan - EMEA/H/C/005089

Rhythm Pharmaceuticals Limited; Treatment of obesity and the control of hunger associated with deficiencies in the leptin-melanocortin pathway

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 13.10.2020.

3.1.3. tirbanibulin mesilate - EMEA/H/C/005183

topical field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 22.04.2021, 25.02.2021. List of Questions adopted on 25.06.2020.

3.1.4. relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267

treatment of uterine fibroids

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 25.03.2021, 28.01.2021. List of Questions adopted on 23.07.2020.

3.1.5. elivaldogene autotemcel - Orphan - ATMP - EMEA/H/C/003690

bluebird bio (Netherlands) B.V; treatment of ABCD1 genetic mutation and cerebral adrenoleukodystrophy

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 16.04.2021. List of Questions adopted on 22.01.2021.

3.1.6. vericiguat - EMEA/H/C/005319

treatment of symptomatic chronic heart failure

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 15.10.2020.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. avalglucosidase alfa - Orphan - EMEA/H/C/005501

Genzyme Europe BV; for long-term enzyme replacement therapy for the treatment of patients with Pompe disease.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 28.01.2021.

3.2.2. ranibizumab - EMEA/H/C/005545

treatment of neovascular age-related macular degeneration (AMD)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 28.01.2021.

3.2.3. roxadustat - EMEA/H/C/004871

treatment of anaemia

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

3.2.4. icatibant - EMEA/H/C/005083

treatment of hereditary angioedema

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 10.12.2020.

3.2.5. bevacizumab - EMEA/H/C/005433

indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

3.2.6. sitagliptin - EMEA/H/C/005598

treatment of type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

3.2.7. sugammadex - EMEA/H/C/005403

treatment of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

3.2.8. tafasitamab - Orphan - EMEA/H/C/005436

Morphosys AG; is indicated in combination with lenalidomide followed by Tafasimab MorphoSys monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. sotorasib - EMEA/H/C/005522

treatment of locally advanced or metastatic non-small cell lung cancer

Scope: List of questions

Action: For adoption

3.3.2. voxelotor - Orphan - EMEA/H/C/004869

Global Blood Therapeutics Netherlan; Indicated for the treatment of haemolytic anaemia in adults and paediatric patients 12 years of age and older with sickle cell disease (SCD).

Scope: List of questions

Action: For adoption

3.3.3. amivantamab - EMEA/H/C/005454

for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Scope: List of questions

Action: For adoption

3.3.4. sapropterin - EMEA/H/C/005646

treatment of hyperphenylalaninemia (HPA)

Scope: List of questions

Action: For adoption

3.3.5. teriparatide - EMEA/H/C/005793

treatment of osteoporosis

Scope: List of questions

Action: For adoption

3.3.6. semaglutide - EMEA/H/C/005422

treatment for weight loss and weight maintenance

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. dabigatran etexilate - EMEA/H/C/005639

prevention of venous thromboembolic events

Scope: Letter from the applicant dated 06 May 2021 requesting an extension of clock-stop to respond to the list of questions adopted in November 2020.

Action: For adoption

List of Questions adopted on 12.11.2020.

3.4.2. pralsetinib - EMEA/H/C/005413

treatment of non-small cell lung cancer (NSCLC)

Scope: Need for SAG consultation

Action: For discussion

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 17.09.2020.

3.4.3. insulin human (rDNA) - EMEA/H/C/005331

treatment of patients with diabetes mellitus who require intravenous insulin

Scope: Letter from the applicant dated 07 May 2021 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in March 2021.

Action: For adoption

List of outstanding issues adopted on 25.03.2021. List of Questions adopted on 23.07.2020.

3.4.4. lenadogene nolparvovec - Orphan - ATMP - EMEA/H/C/005047

GenSight Biologics S.A.; treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)

Scope: Letter from the applicant dated 22 April 2021 requesting an extension of clock-stop to respond to the list of questions adopted in February 2021.

Action: For information

List of Questions adopted on 25.02.2021.

3.4.5. metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678

treatment of type 2 diabetes mellitus

Scope: Letter from the applicant dated 07 May 2021 requesting an extension of clock-stop

to respond to the list of questions adopted in March 2021.

Action: For adoption

List of Questions adopted on 25.03.2021.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Bortezomib Accord - bortezomib - EMEA/H/C/003984/X/0023

Accord Healthcare S.L.U.

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (2.5 mg/ml solution for injection)."

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

4.1.2. Cosentyx - secukinumab - EMEA/H/C/003729/X/0067

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension application to introduce a new strength of 75 mg solution for injection."

Action: For adoption

List of Questions adopted on 25.02.2021.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Deltyba - delamanid - Orphan - EMEA/H/C/002552/X/0046/G

Otsuka Novel Products GmbH

Rapporteur: Christophe Focke, PRAC Rapporteur: Laurence de Fays

Scope: "Extension application to introduce a new pharmaceutical form (dispersible tablets) associated with a new strength (25 mg), grouped with a type II extension of indication variation (C.I.6.a) to include the treatment of children of at least 10 kg of body weight for the approved Deltyba 50 mg film-coated tablets; as a consequence, sections 3, 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated accordingly. Version 3.3 of the RMP has also been submitted and Annex II is updated to remove the specific obligation related to an in vitro study using the HFS-TB model."

Action: For adoption

List of Questions adopted on 10.12.2020.

4.2.2. Rinvoq - upadacitinib - EMEA/H/C/004760/X/0006/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension application to introduce a new strength (30 mg prolonged-release tablet), grouped with a type II variation (C.I.6.a) to add a new indication (treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy for Rinvoq).
As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC as well as the Package Leaflet are updated.
The RMP (version 4.0) is updated in accordance.
In addition, the marketing authorisation holder (MAH) took the opportunity to include a minor update in the Annex II."

Action: For adoption

List of Questions adopted on 25.02.2021.

4.2.3. Volibris - ambrisentan - EMEA/H/C/000839/X/0061/G

GlaxoSmithKline (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension application to introduce a new strength (2.5 mg film-coated tablet), grouped with an extension of indication to include paediatric use (8 to less than 18 years). Version 9.0 of the RMP has been submitted.
Type IA category A.7."

Action: For adoption

List of Questions adopted on 17.09.2020.

4.2.4. Vosevi - sofosbuvir / velpatasvir / voxilaprevir - EMEA/H/C/004350/X/0045/G

Gilead Sciences Ireland UC

Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension application to introduce a new strength (200 mg /50 mg /50 mg film-coated tablets). The new presentation is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older OR weighing at least 30 kg. In addition, the MAH took the opportunity to implement minor editorial updates.
The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 12 years and older OR weighing at least 30 kg to the existing presentation. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.2) is updated in accordance."

Action: For adoption

List of Questions adopted on 25.02.2021.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Ozempic - semaglutide - EMEA/H/C/004174/X/0021

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Annika Folin

Scope: "Extension application to add a new strength of 2 mg solution for injection."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Blincyto - blinatumomab - Orphan - EMEA/H/C/003731/II/0038

Amgen Europe B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication to include the use of blinatumomab as monotherapy for the treatment of paediatric patients aged 1 year or older with high risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as consolidation therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021.

5.1.2. Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0110

GlaxoSmithkline Biologicals SA

Rapporteur: Christophe Focke, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication to include the prevention of head and neck cancers causally related to certain oncogenic human papillomavirus types for Cervarix; as a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 23.0 of the RMP has also been submitted to mainly reflect the updated indication.
In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020.

5.1.3. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0043

Janssen-Cilag International NV

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include treatment of adult patients with systemic light chain (AL) amyloidosis for Darzalex; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021.

5.1.4. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0044

Janssen-Cilag International NV

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication for Darzalex subcutaneous formulation to include combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 4.8 of the SmPC for the intravenous formulation is also updated based on the pooled safety analysis. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021.

5.1.5. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0011

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "To modify the approved therapeutic indication to include conditions for the eligibility to pre-vaccination serostatus screening. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC and sections 1, 2 and 3 of the Package Leaflet are updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.6. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0012

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "Extension of indication to include paediatric population from 6 years of age for Dengvaxia; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and sections 1, 2 and 4 of the Package Leaflet are updated. Furthermore, the MAH takes the opportunity to add an instruction for the installation of the needle in the SmPC and the Package Leaflet of the single-dose presentation."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.7. Evotaz - atazanavir / cobicistat - EMEA/H/C/003904/II/0038

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Adrien Inoubli

Scope: "Extension of indication to include the use of Evotaz in combination with other antiretroviral agents in the treatment of HIV-1 infection in adolescent patients aged ≥ 12 to < 18 years, weighing ≥ 35 kg without known mutations associated with resistance to atazanavir; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial corrections."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

5.1.8. Jardiance - empagliflozin - EMEA/H/C/002677/II/0055

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include treatment of adult patients with heart failure and reduced ejection fraction for Jardiance; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9 and 5.1 of the SmPC are updated. This is based on final results from the EMPEROR HFrEF study, a phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo. The Package Leaflet and Labelling are updated in accordance. Version 15.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 22.04.2021, 28.01.2021.

5.1.9. Jyseleca - filgotinib - EMEA/H/C/005113/II/0001

Gilead Sciences Ireland UC

Rapporteur: Kristina Dunder, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "C.I.6 (Extension of indication) C.I.6a (Extension of indication). Extension of indication to include the treatment of active ulcerative colitis in adults patients for Jyseleca. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly. Version 1.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to do minor updates to the Annex II and to implement minor editorial changes in the SmPC and Package

Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021.

5.1.10. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0097

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults for Keytruda, based on the results from the pivotal KEYNOTE-590 (KN590) trial. Phase 3, randomized, double-blind, placebo-controlled, multisite study to evaluate the efficacy and safety of pembrolizumab in combination with chemotherapy (cisplatin and 5-FU) versus chemotherapy (cisplatin with 5-FU) as first-line treatment in participants with locally advanced unresectable metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction; as a consequence sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version of the RMP (Version 30.1) has also been submitted."

Action: Possible oral explanation to be held on 18 May 2021 at 14:00

Request for Supplementary Information adopted on 22.04.2021, 25.02.2021.

See 2.3

5.1.11. Libtayo - cemiplimab - EMEA/H/C/004844/II/0011

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Libtayo as monotherapy indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumor cells), with no EGFR, ALK or ROS1 aberrations, who have:
• locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or have progressed after treatment with definitive chemoradiation, or
• metastatic NSCLC.
The PL is revised accordingly. A revised RMP is submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020.

5.1.12. Libtayo - cemiplimab - EMEA/H/C/004844/II/0012

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include: Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.
SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 have been revised. The PL has been updated accordingly. A revised RMP has been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020.

5.1.13. Lorviqua - lorlatinib - EMEA/H/C/004646/II/0015

Pfizer Europe MA EEIG

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor based on results from the phase III randomised CROWN (1006) study listed as a specific obligation (SOB) in the Annex II; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package leaflet is updated accordingly. Version 3.0 of the RMP has also been submitted. In addition, the applicant proposes to downgrade the specific obligation to conduct a single arm study in patients who progressed after alectinib or ceritinib to a recommendation and convert the conditional MA to a full MA."

Action: For adoption

5.1.14. Siklos - hydroxycarbamide - EMEA/H/C/000689/II/0047

Addmedica S.A.S.

Rapporteur: Karin Janssen van Doorn

Scope: "Extension of indication to include treatment of severe chronic anemia (haemoglobin level < 6 g/dL or < 7 g/dL with poor clinical or functional tolerance) in adults, adolescents and children older than 2 years suffering from sickle cell syndrome for Siklos; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021, 15.10.2020.

5.1.15. Spherox - spheroids of human autologous matrix-associated chondrocytes - ATMP - EMEA/H/C/002736/II/0020

CO.DON AG

Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder

Scope: "Extension of the indication for use in the paediatric population (15 to 18 years)."

Action: For adoption

Request for Supplementary Information adopted on 19.03.2021.

5.1.16. Tookad - padeliporfin - EMEA/H/C/004182/II/0013

STEBA Biotech S.A

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maia Uusküla

Scope: "Modification of the wording of the existing indication. The new wording will be the treatment of adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and Clinical stage T1c or T2a, ISUP Grade Group ≤ 2, based on high-resolution biopsy strategies, PSA ≤ 10 ng/mL, Low core positivity for Tookad; as a consequence, section 4.1 of the SmPC is updated. Version 6.0 of the RMP has also been submitted."

Action: For adoption

5.1.17. Veklury - remdesivir - EMEA/H/C/005622/II/0016

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication to include treatment of adults with pneumonia not requiring supplemental oxygen (moderate COVID-19), based on Part A of study GS-US-540-5774, a Phase 3, randomized, open-label, multicenter study comparing 2 RDV regimens (5 days and 10 days) versus standard of care in 584 participants with moderate COVID 19, and study CO US 540 5776 [Adaptive COVID-19 Treatment Trial (ACTT) 1, a National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Phase 3, randomized, double blind, placebo controlled, multicenter study]. As a consequence, sections 4.1 and 5.1 of the SmPC are being updated, and the Package Leaflet is updated in accordance. A revised version 1.2 of the RMP has also been submitted."

Action: For adoption

5.1.18. Vyxeos liposomal - daunorubicin / cytarabine - Orphan - EMEA/H/C/004282/II/0018/G

Jazz Pharmaceuticals Ireland Limited

Rapporteur: Johanna Lähteenvuo, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to add treatment of relapsed/refractory AML in paediatric patients with subsequent updates to sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC based on the new safety and efficacy data from the paediatric clinical study AAML1421. The Package leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the PI is updated in line with the latest QRD template 10.2.
Submission of the final data from paediatric clinical study CPX-MA-1201 in support of the extension of indication.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.19. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0035

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy for Xeljanz film-coated tablets; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 17.1 of the RMP has also been submitted."

Action: For adoption

5.1.20. WS1840 Opdivo - nivolumab - EMEA/H/C/003985/WS1840/0089 Yervoy - ipilimumab - EMEA/H/C/002213/WS1840/0084

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC) for combination treatment with Opdivo and Yervoy; as a consequence, sections 4.1, 4.2 ,4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.0 for Opdivo and version 29.0 for Yervoy of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 12.11.2020.

5.1.21. WS1937/G Eucreas - vildagliptin / metformin hydrochloride - EMEA/H/C/000807/WS1937/0080/G Icandra - vildagliptin / metformin hydrochloride - EMEA/H/C/001050/WS1937/0083/G Zomarist - vildagliptin / metformin hydrochloride - EMEA/H/C/001049/WS1937/0082/G

Novartis Europharm Limited

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: "Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study). Existing warning on drugs that may affect renal function or metformin disposition was expanded to include drugs that inhibit renal transporter (OCT2/MATE inhibitors) and corresponding update in drug interaction (section 4.4 and 4.5). PI update to QRD v10.1."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 28.01.2021.

5.1.22. WS1938/G
Galvus - vildagliptin - EMEA/H/C/000771/WS1938/0066/G
Jalra - vildagliptin - EMEA/H/C/001048/WS1938/0068/G
Xiliarx - vildagliptin - EMEA/H/C/001051/WS1938/0066/G

Novartis Europharm Limited

Lead Rapporteur: Kristina Dunder

Scope: "Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study)."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 28.01.2021.

5.1.23. WS1941
Edistride - dapagliflozin - EMEA/H/C/004161/WS1941/0043
Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062

AstraZeneca AB

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC for Forxiga and Edistride based on the results from the renal outcomes study D169AC00001 (DAPA-CKD). The Annex II.B and Package Leaflet of these products are updated accordingly. The DAPA-CKD study is a category 3, Post-Authorisation Safety Study (PASS) listed in the dapagliflozin RMP to evaluate the potential risk of lower limb amputation; it is a multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death. In addition, the Risk Management Plan for dapagliflozin (version 22) has been updated."

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. valoctocogene roxaparvovec - Orphan - ATMP - H0005830

BioMarin International Limited; indicated for the treatment of adults with severe haemophilia A (congenital factor VIII deficiency) without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).
Is not indicated for use in women of childbearing potential.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0030

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, Co-Rapporteur: Jean Michel Race, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of the existing indication from "individuals 16 years of age and older" to "individuals 12 years of age and older" for Comirnaty; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted."

Action: For information

9.1.2. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0013

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "To update sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a new posology regimen from 3 doses to 2 doses for individuals from 9 years of age based on interim results from study CYD65 listed as a category 3 study in the RMP; this is a Phase II, observer-blind, placebo-controlled trial in order to assess Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules Followed by a Single Booster; section 3 of the Package Leaflet is updated accordingly"

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

9.1.3. Kengrexal – cangrelor - EMEA/H/C/003773/P46/003

Chiesi Farmaceutici S.p.A.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alar Irs

Scope: "The MAH submitted a completed paediatric study (MDCO-CAN-15-01-CSR-01830) for Kengrexal 50 mg Powder for concentrate for solution for injection / infusion, in accordance with Article 46 of Regulation (EC) No1901/2006, as amended."

Action: For information

9.1.4. Ledaga - chlormethine – Orphan - EMEA/H/C/002826/II/0027

Helsinn Birex Pharmaceuticals Limited

Rapporteur: Sinan B. Sarac

Scope: "Update of section 4.2 of the SmPC in order to allow flexibility in the starting frequency of the treatment based on current clinical practice; the Package Leaflet is updated accordingly."

Action: For adoption

9.1.5. Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0003

Alexion Europe SAS

Rapporteur: Jan Mueller-Berghaus

Scope: "Submission of the final report from Population PK and PK/PD Modelling Report (POR-PKPD-ADEX-321) listed as a category 2 study in the RMP/Specific Obligation 004 in Annex II."

Scope: List of outstanding issues

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021, 28.05.2020, 12.12.2019.

9.1.6. Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0009/G

Alexion Europe SAS

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "C.I.4, C.I.3, C.I.6 (non-EoI)
Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on results from study CSR 19-514 (PK Comparability) and CSR 16-508 (Japanese Ethnicity Study) listed as a specific obligation in the Annex II. Annex II was proposed to be updated accordingly. The RMP version 2.1 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020, 30.04.2020.

9.1.7. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0014

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Update of sections 4.3, 4.4 and 4.8 of the SmPC, following an update to the Company Core Data Sheet in relation to thromboembolism with thrombocytopenia, to contraindicate the vaccine to patients who have experienced major venous and/or arterial thrombosis in combination with thrombocytopenia following vaccination with any COVID-19 vaccine, update the warnings on thrombocytopenia and coagulation disorders and include

the frequency thrombosis with thrombocytopenia of "less than 1/100,000". The package leaflet is updated accordingly."

Action: For discussion

9.1.8. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0015

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Submission of an updated RMP version 3.1 in order to update the safety concerns to add 'Thrombosis in combination with thrombocytopenia' as an important identified risk and 'Thrombosis' as an important potential risk, with consequential changes in the RMP. Updates to the Pharmacovigilance Plan have also been implemented. These changes were requested by PRAC in the outcome of Signal Assessment Procedure on Embolic and Thrombotic Events with Vaxzevria EPITT no: 196833. The MAH has taken the opportunity to further update the RMP to reclassify "anaphylaxis" as an important identified risk, already reflected in the product information as an adverse reaction."

Action: For discussion

9.1.9. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0017/G

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "C.I.4 (type II) - Update of section 4.6 of the SmPC in order to add the high-level results from the development and reproductive toxicity (DART) study (study number 490843).
C.I.4 (type II) - Update of section 5.3 of the SmPC in order to add the high-level results from the biodistribution study (study number 514559), listed as an imposed study in Annex II.
The MAH is taking the opportunity to update the wording of section 5.3 of the SmPC to add the results from the already assessed repeat-dose toxicity study. Moreover, the MAH is taking the opportunity to address the nonclinical recommendations adopted during the initial CMA application."

Action: For discussion

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Sotrovimab (VIR-7831/GSK4182136) for the treatment of COVID-19 - EMEA/H/A-5(3)/1508

GlaxoSmithKline

Referral Rapporteur: Kirstine Moll Harboe, Referral Co-Rapporteur: Jayne Crowe

Scope: Opinion

Rapporteurs were appointed via written procedures on 14.04.2021

Action: For adoption

The Committee for Medicinal Products for Human Use (CHMP) has been asked by the EMA to give a scientific opinion under Article 5(3) of Regulation (EC) No 726/2004 on the currently available quality, preclinical and clinical data on the potential use of GSK4182136 (VIR-7831) for the treatment of patients with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

May 2021 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2021

Action: For adoption

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP May 2021 meeting to CHMP for adoption

Action: For adoption

14.3.2. Modelling and Simulation Working Party (MSWP)

Chairs: Kristin Karlsson/Flora Musuamba Tshinanu

Election of MSWP Chair and Vice-Chair. The mandate of MSWP chair Kristin Karlsson and MSWP vice-chair Flora Musuamba Tshinanu will expire on 28 June 2021.

Nomination(s) received

Action: For election

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 03-06 May 2021. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Marketing Authorisation Applications 3-year forecast report

Action: For information

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

15.1.2. Scientific Advice Group (SAG) re-nominations

Follow up on the public call for expression of interests for renewal of mandate of all therapeutic SAGs

Action: For information

15.1.3. COVID-19 vaccine (NVX-CoV2373) – EMEA/H/C/005808

prevention of COVID-19

Scope: Rolling review timetable adopted via written procedure on 29 April 2021

Action: For information

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 May 2021
EMA/CHMP/276671/2021

Annex to 17-20 May 2021 CHMP Agenda

Pre submission and post authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for
May 2021: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for
May 2021: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

**SCENESSE - afamelanotide -
EMEA/H/C/002548/S/0035, Orphan**
Clinuvel Europe Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

**Emtricitabine/Tenofovir disoproxil Zentiva
- emtricitabine / tenofovir disoproxil -
EMEA/H/C/004137/R/0019**
Zentiva k.s., Generic, Generic of Truvada, Rapporteur: Alar Irs, PRAC Rapporteur: Ana Sofia Diniz Martins

Tenofovir disoproxil Zentiva - tenofovir disoproxil - EMEA/H/C/004120/R/0023
Zentiva k.s., Generic, Generic of Viread, Rapporteur: John Joseph Borg, PRAC Rapporteur: Adrien Inoubli
Request for Supplementary Information adopted

on 25.03.2021.

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Glyxambi - empagliflozin / linagliptin - EMEA/H/C/003833/R/0039
Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Eva A. Segovia

IBRANCE - palbociclib - EMEA/H/C/003853/R/0034
Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Anette Kirstine Stark

Ivabradine Zentiva - ivabradine - EMEA/H/C/004117/R/0008
Zentiva k.s., Generic, Generic of Procoralan, Rapporteur: Tomas Radimersky, PRAC Rapporteur: Menno van der Elst

Mysildecard - sildenafil - EMEA/H/C/004186/R/0009
Mylan S.A.S, Generic, Generic of Revatio, Rapporteur: Ondřej Slanař, PRAC Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 22.04.2021.

Onivyde pegylated liposomal - irinotecan hydrochloride trihydrate - EMEA/H/C/004125/R/0025, Orphan
Les Laboratoires Servier, Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: David Olsen

Rekovelle - follitropin delta - EMEA/H/C/003994/R/0028
Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst

XALKORI - crizotinib - EMEA/H/C/002489/R/0071
Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Tiphaine Vaillant

B.2.3. Renewals of Conditional Marketing Authorisations

AYVAKYT - avapritinib -
EMEA/H/C/005208/R/0007, Orphan
Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Menno van der Elst

Idefirix - imlifidase -
EMEA/H/C/004849/R/0003, Orphan
Hansa Biopharma AB, Rapporteur: Martina Weise, PRAC Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 22.04.2021.

Veklury - remdesivir -
EMEA/H/C/005622/R/0015
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Eva Jirsová
Request for Supplementary Information adopted on 25.03.2021.

VITRAKVI - larotrectinib -
EMEA/H/C/004919/R/0014
Bayer AG, Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 03-06 May 2021
PRAC:

Signal of Sarcoidosis

Lemtrada - alemtuzumab
Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Anette Kirstine Stark
PRAC recommendation on a variation
Action: For adoption

Signal of localised swelling in persons with history of dermal filler injections

Comirnaty – tozinameran
Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst
PRAC recommendation on a variation
Action: For adoption

Signal of Cardiac arrhythmia

Evenity – romosozumab
Rapporteur: Kristina Dunder, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Tiphaine Vaillant
PRAC recommendation on a variation
Action: For adoption

Signal of Henoch-Schoenlein purpura

Cosentyx – secukinumab
Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Eva A. Segovia
PRAC recommendation on a variation
Action: For adoption

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its May 2021 meeting:

EMEA/H/C/PSUSA/00002283/202009
(panitumumab)
CAPS:
Vectibix (EMEA/H/C/000741) (panitumumab), Amgen Europe B.V., Rapporteur: Bjorg Bolstad, PRAC Rapporteur: David Olsen, "29/09/2019 To: 29/09/2020"

EMEA/H/C/PSUSA/00002710/202009
(sirolimus)
CAPS:
Rapamune (EMEA/H/C/000273) (sirolimus), Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "15/09/2017 To: 14/09/2020"

EMEA/H/C/PSUSA/00002919/202010
(thalidomide)
CAPS:
Thalidomide Celgene (EMEA/H/C/000823) (thalidomide), Celgene Europe BV, Rapporteur: Alexandre Moreau
NAPS:

NAPs - EU PRAC Rapporteur: Tiphaine Vaillant, "10/10/2019 To 09/10/2020"
EMEA/H/C/PSUSA/00010052/202009 (vortioxetine) CAPS: **Brintellix** (EMEA/H/C/002717) (vortioxetine), H. Lundbeck A/S, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Laurence de Fays, "29/09/2019 To 29/09/2020"
EMEA/H/C/PSUSA/00010135/202009 (teriflunomide) CAPS: **AUBAGIO** (EMEA/H/C/002514) (teriflunomide), sanofi-aventis groupe, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "12/09/2017 To: 12/09/2020"
EMEA/H/C/PSUSA/00010655/202009 (niraparib) CAPS: **Zejula** (EMEA/H/C/004249) (niraparib), GlaxoSmithKline (Ireland) Limited, Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Jan Neuhauser, "27/03/2020 To: 26/09/2020"
EMEA/H/C/PSUSA/00010733/202009 (galcanezumab) CAPS: **Emgality** (EMEA/H/C/004648) (galcanezumab), Eli Lilly Nederland B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Kirsti Villikka, "28/03/2020 To: 27/09/2020"

B.4. EPARs / WPARs

Abiraterone Krka - abiraterone acetate - EMEA/H/C/005649 KRKA, d.d., Novo mesto, treatment of prostate cancer in adult men, Generic, Generic of Zytiga, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Adtralza - tralokinumab - EMEA/H/C/005255 LEO Pharma A/S, treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

Celsunax - ioflupane (123I) - EMEA/H/C/005135 Pinax Pharma GmbH, is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum, Generic, Generic of DaTSCAN, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Enspryng - satralizumab - EMEA/H/C/004788, Orphan Roche Registration GmbH, treatment of adult and adolescent patients from 12 years of age with neuromyelitis optica spectrum disorders (NMOSD), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
EVKEEZA - evinacumab - EMEA/H/C/005449 Regeneron Ireland Designated Activity Company (DAC), treatment of homozygous familial hypercholesterolemia (HoFH), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Jayempi - azathioprine - EMEA/H/C/005055 Nova Laboratories Ireland Limited, indicated for the prophylaxis of transplant rejection, used as an immunosuppressant antimetabolite, chronic inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis), relapsing multiple sclerosis, generalised myasthenia gravis, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Koselugo - selumetinib - EMEA/H/C/005244, Orphan AstraZeneca AB, treatment of neurofibromatosis type 1 (NF1), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Onureg - azacitidine - EMEA/H/C/004761 Bristol-Myers Squibb Pharma EEIG, treatment for acute myeloid leukaemia, Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0088/G, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik	
BESPONSA - inotuzumab ozogamicin - EMEA/H/C/004119/II/0020/G, Orphan Pfizer Europe MA EEIG, Rapporteur: Filip Josephson Opinion adopted on 06.05.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Biopoin - epoetin theta - EMEA/H/C/001036/II/0048 TEVA GmbH, Rapporteur: Alexandre Moreau	
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0027 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 27.04.2021.	Positive Opinion adopted by consensus on 27.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0028/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 07.05.2021.	Positive Opinion adopted by consensus on 07.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COVID-19 Vaccine Moderna - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0013/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus	
Cufence - trientine dihydrochloride - EMEA/H/C/004111/II/0007/G Univar Solutions BV, Rapporteur: Daniela Philadelphy Request for Supplementary Information adopted on 09.04.2021.	
Darunavir Mylan - darunavir - EMEA/H/C/004068/II/0012 Mylan S.A.S, Generic, Generic of Prezista, Rapporteur: John Joseph Borg Opinion adopted on 29.04.2021. Request for Supplementary Information adopted on 25.03.2021, 14.01.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Darzalex - daratumumab - EMEA/H/C/004077/II/0048/G, Orphan Janssen-Cilag International NV, Rapporteur:	

Sinan B. Sarac	
Dupixent - dupilumab - EMEA/H/C/004390/II/0043/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus	
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004240/II/0015/G Mylan S.A.S, Generic, Generic of Atripla, Rapporteur: Bruno Sepodes	
Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0055 Merck Sharp & Dohme B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 25.03.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0057 Merck Sharp & Dohme B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 25.03.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Eporatio - epoetin theta - EMEA/H/C/001033/II/0047 ratiopharm GmbH, Rapporteur: Alexandre Moreau	
EVRA - ethinylestradiol / norelgestromin - EMEA/H/C/000410/II/0048/G Janssen-Cilag International NV, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 14.01.2021.	
HBVAXPRO - hepatitis B vaccine (rDNA) - EMEA/H/C/000373/II/0071/G MSD Vaccins, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 29.04.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Herzuma - trastuzumab - EMEA/H/C/002575/II/0038 Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus	
HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0068/G Baxalta Innovations GmbH, Rapporteur: Jan	

Mueller-Berghaus	
IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0064 Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus	
Luveris - lutropin alfa - EMEA/H/C/000292/II/0089 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe Opinion adopted on 06.05.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
MenQuadfi - Meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/005084/II/0001/G Sanofi Pasteur, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 09.04.2021.	
Myalepta - metreleptin - EMEA/H/C/004218/II/0017/G, Orphan Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 04.02.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ogivri - trastuzumab - EMEA/H/C/004916/II/0028 Mylan S.A.S, Rapporteur: Karin Janssen van Doorn	
Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/II/0072 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe Opinion adopted on 29.04.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Resolor - prucalopride - EMEA/H/C/001012/II/0052 Shire Pharmaceuticals Ireland Limited, Rapporteur: Kristina Dunder	
Ruconest - conestat alfa - EMEA/H/C/001223/II/0063 Pharming Group N.V, Rapporteur: Andrea Laslop	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0076/G MCM Vaccine B.V., Rapporteur: Christophe	

Focke	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0016 AstraZeneca AB, Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 12.05.2021.	Request for supplementary information adopted with a specific timetable.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0018 AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 12.05.2021.	Positive Opinion adopted by consensus on 12.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Xenical - orlistat - EMEA/H/C/000154/II/0083 CHEPLAPHARM Arzneimittel GmbH, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 18.02.2021, 15.10.2020.	
WS1981 **Abseamed-EMEA/H/C/000727/ WS1981/0093** **Binocrit-EMEA/H/C/000725/ WS1981/0092** **Epoetin alfa Hexal-EMEA/H/C/000726/ WS1981/0092** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 11.03.2021.	
WS2012/G **Infanrix hexa-EMEA/H/C/000296/ WS2012/0297/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke	
WS2018/G **Ambirix-EMEA/H/C/000426/WS2018/ 0114/G** **Twinrix Adult-EMEA/H/C/000112/ WS2018/0149/G** **Twinrix Paediatric-EMEA/H/C/000129/ WS2018/0150/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Akynzeo - fosnetupitant / netupitant / palonosetron - EMEA/H/C/003728/II/0034 Helsinn Birex Pharmaceuticals Limited, Rapporteur: Peter Kiely, "Submission of the results of the in vitro study assessing the ability of fosnetupitant to inhibit all UGTs of interest: UGT1A1, 1A3, 1A4, 1A6, 1A9, and 2B7 following a recommendation from the CHMP." Request for Supplementary Information adopted on 25.03.2021.	
Alecensa - alectinib - EMEA/H/C/004164/II/0034 Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add haemolytic anaemia to the list of adverse drug reactions (ADRs) with frequency common, based on a report of cumulative safety data (DSR1104210); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2. Moreover, the MAH took the opportunity to introduce editorial changes in the Greek, Swedish, Dutch, Danish, Latvian, Croatian, Portuguese and Czech PI."	
Brilique - ticagrelor - EMEA/H/C/001241/II/0050 AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of the SmPC in order to add central sleep apnoea including Cheyne-Stokes respiration as a new warning in section 4.4. and in the list of adverse drug reactions (ADRs) section 4.8 with frequency not known, following collection of post-marketing data; the Package Leaflet is updated accordingly."	
Brineura - cerliponase alfa - EMEA/H/C/004065/II/0029, Orphan BioMarin International Limited, Rapporteur: Martina Weise, "The postponement of the submission date of the final CSR for Study BMN190-202 till October 2021." Opinion adopted on 29.04.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Calquence - acalabrutinib - EMEA/H/C/005299/II/0004 AstraZeneca AB, Rapporteur: Filip Josephson, "Submission of the final report of the nonclinical study 20266648 (5336BV) (Acalabrutinib:	

Neutral Red Uptake Phototoxicity Assay in BALB/c 3T3 Mouse Fibroblasts), in response to the CHMP recommendation to submit results from a modified 3T3 NRU phototoxicity study with adjusted wavelengths. This variation does not propose amendments to the PI."	
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0023/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
Darzalex - daratumumab - EMEA/H/C/004077/II/0047, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 4.4 of the SmPC in order to include a fatal outcome for IRRs following a systematic cross-programmatic review of fatal cases of Infusion Related Reaction (IRR) with use of daratumumab. In addition, the MAH has taken the opportunity to correct in section 4.8 the reported incidence rate of Grade 3 or 4 treatment-emergent infections from study MMY3003 for DRd from 27% to 28%." Request for Supplementary Information adopted on 09.04.2021.	
Deltyba - delamanid - EMEA/H/C/002552/II/0048, Orphan Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, "Update of section 5.1 of the SmPC in order to include information on epidemiological cut-off and clinical breakpoint. In addition, the MAH took the opportunity to propose an editorial update in Annex II and Spanish translation of SmPC section 4.8." Opinion adopted on 29.04.2021. Request for Supplementary Information adopted on 11.03.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0013 Sanofi Pasteur, Rapporteur: Christophe Focke, "To update sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a new posology regimen from 3 doses to 2 doses for individuals from 9 years of age based on interim results from study CYD65 listed as a category 3 study in the RMP; this is a Phase II, observer-blind, placebo-controlled trial in order to assess	See 9.1

Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules Followed by a Single Booster; section 3 of the Package Leaflet is updated accordingly" Request for Supplementary Information adopted on 10.12.2020.

Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0019

ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to add data on efficacy and safety in treatment experienced, virologically suppressed subjects switching to the Dovato fixed dose combination tablet, based on the week 96 data results from the Phase III study 204862 (TANGO)."

Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0020

ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 4.8 in order to add new safety information regarding hepatic safety and section 5.1 to include long-term efficacy and safety information, based on studies 204861 (GEMINI-1) and 205543 (GEMINI-2), listed as category 3 studies in the RMP. GEMINI-1 and GEMINI-2 were Phase III, randomised, double-blind, multicentre, parallel group, non-inferiority studies evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Dupixent - dupilumab - EMEA/H/C/004390/II/0039

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, "To update section 4.8 of the SmPC to replace tables of adverse drug reactions per indication with a consolidated table of adverse drug reactions across all approved indications as agreed in the latest PSUR (EMEA/H/C/PSUSA/00010645/202003). The Package Leaflets are updated accordingly." Request for Supplementary Information adopted on 28.01.2021.

Dupixent - dupilumab - EMEA/H/C/004390/II/0044

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, "C.I.4 – Update section 4.8 of the SmPC to include the long-term safety data of dupilumab in adult patients with moderate to severe AD, following interim results from the OLE study (R668-AD-1225) listed as category 3 study in the RMP."	
Erleada - apalutamide - EMEA/H/C/004452/II/0013 Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy, and update of non-clinical information following results of a developmental toxicity study in rats." Request for Supplementary Information adopted on 06.05.2021.	Request for supplementary information adopted with a specific timetable.
Fasenra - benralizumab - EMEA/H/C/004433/II/0031 AstraZeneca AB, Rapporteur: Fátima Ventura, "C.I.13: Submission of the final report from study D3250C00037 (MELTEMI), listed as a category 3 study in the RMP. This is an open-label safety extension study to evaluate the safety and tolerability of a fixed 30 mg dose of benralizumab s.c. in severe asthma patients" Request for Supplementary Information adopted on 06.05.2021, 11.02.2021.	Request for supplementary information adopted with a specific timetable.
Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0003 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, "Update of section 5.1 of the SmPC in order to introduce effectiveness information of Fluad (trivalent formulation) in the product information of Fluad Tetra based on the results from three retrospective observational studies "CORE 17-18 and 18-19", "HEOR 17-18" and "HEOR 18-19") and a randomised clinical trial "LTCF 16-17"." Request for Supplementary Information adopted on 28.01.2021, 15.10.2020.	
Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/II/0070/G Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, "- C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and the	

thienopyridine anti-platelet drugs clopidogrel and prasugrel, based on a MAH cumulative safety review. The Package Leaflet is updated accordingly. - C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and medicinal products or oral supplements containing polyvalent cations, based on a MAH cumulative safety review. The Package Leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to correct the amount of lactose stated in section 2 of the SmPC and make minor editorial changes throughout the PI." Request for Supplementary Information adopted on 11.03.2021, 10.12.2020.	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0028 AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Submission of the final analyses of the CASPIAN study for the Durvalumab (D) + Tremelimumab (T) + etoposide-platinum chemotherapy (EP) vs. EP treatment comparison as recommended by the CHMP in the context of procedure EMEA/H/C/004771/II/0014/G. In addition, the MAH submits the results from the China Cohort incorporated in the CASPIAN study. This is an interventional study investigating the efficacy and safety of D ± T in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)." Opinion adopted on 29.04.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Kineret - anakinra - EMEA/H/C/000363/II/0080/G Swedish Orphan Biovitrum AB (publ), Rapporteur: Kirstine Moll Harboe, "Update of section 4.4 of the SmPC in order to include new safety information about Macrophage activation syndrome (MAS) in the 'serious infections' subsection and to update the 'pulmonary events' and the 'malignancies' subsections with new safety information. Update of section 4.8 of the SmPC to amend the summary of safety profile, the 'serious infections', the 'neutropenia', 'allergic reactions',	Request for supplementary information adopted with a specific timetable.

'immunogenicity', 'paediatric population' and the 'injection site reactions' subsections with new safety information. Update of section 5.1 of the SmPC to update the clinical efficacy and safety information in Still's disease. The updates proposed are based on the results from study Sobi.ANAKIN-301 (evaluated in procedure no. EMA/H/C/000363/P46/031) and Sobi.ANAKIN-302 (evaluated in procedure no. EMEA/H/C/000363/II/0073). Sobi.ANAKIN-301 was a randomised, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of anakinra as compared to placebo in newly diagnosed Still's disease patients (including systemic juvenile idiopathic arthritis [SJIA] and adult-onset Still's disease [AOSD]). Sobi.ANAKIN-302 was a non-interventional, post-authorisation safety study to evaluate long-term safety of anakinra in patients with SJIA." In addition, the MAH took the opportunity to correct in section 4.8 of the SmPC the frequency of the adverse reaction 'skin and subcutaneous tissue disorder' from 'very common' to 'uncommon'." Request for Supplementary Information adopted on 06.05.2021.	
LEDAGA - chlormethine - EMEA/H/C/002826/II/0027, Orphan Helsinn Birex Pharmaceuticals Limited, Rapporteur: Sinan B. Sarac, "Update of section 4.2 of the SmPC in order to allow flexibility in the starting frequency of the treatment based on current clinical practice; the Package Leaflet is updated accordingly."	See 9.1
Lynparza - olaparib - EMEA/H/C/003726/II/0044 AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of sections 4.8 and 5.1 of the SmPC of Lynparza tablets based on updated efficacy and safety data from the Phase III PAOLA-1 study. In addition, the MAH took the opportunity to switch the order of the capsule and tablet formulations in Annex I of the PI." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 11.03.2021.	
Lynparza - olaparib - EMEA/H/C/003726/II/0045 AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of section 5.1 of the SmPC of Lynparza capsules based on the final report from study/D0816C00012 (ORZORA) listed as PAES in the Annex II of the Product Information. This is an Open Label, Single Arm, Multi-centre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. The Annex II is updated accordingly." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 18.03.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Mavenclad - cladribine - EMEA/H/C/004230/II/0016 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, "C.I.4 Update of section 4.8 of the SmPC in order to add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency "common" based on a review of cumulative clinical and post-marketing data. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 14.01.2021.	
Nerlynx - neratinib - EMEA/H/C/004030/II/0021 Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Update of sections 5.3 and 6.6 of the SmPC based on an updated environmental risk assessment including ERA studies"	
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0003 Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from Population PK and PK/PD Modelling Report (POR-PKPD-ADEX-321) listed as a category 2 study in the RMP/Specific Obligation 004 in Annex II." Request for Supplementary Information adopted on 25.02.2021, 28.05.2020, 12.12.2019.	See 9.1
Phesgo - pertuzumab / trastuzumab -	Request for supplementary information adopted

EMEA/H/C/005386/II/0002 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to support the safety of switching from intravenous to subcutaneous route of administration or vice versa, based on results from study MO40628; this is a Phase II, randomised, open-label, cross-over study to assess preference for intravenous or subcutaneous route of administration in patients with HER2-positive early breast cancer." Request for Supplementary Information adopted on 29.04.2021.	with a specific timetable.
Sunosi - solriamfetol - EMEA/H/C/004893/II/0009 Jazz Pharmaceuticals Ireland Limited, Rapporteur: Janet Koenig, "Update of section 4.8 of the SmPC in order to add hypersensitivity reactions to the list of adverse drug reactions (ADRs) following confirmation of a post-marketing safety signal for hypersensitivity. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes and to bring the PI in line with the latest QRD template version 10.2." Request for Supplementary Information adopted on 29.04.2021.	Request for supplementary information adopted with a specific timetable.
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0058 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 5.1 of the SmPC in order to include the updated efficacy results from study YO40245 (IMbrave150) with a data cut-off of 31 August 2020 as recommended by the CHMP in the context of variation EMEA/H/C/004143/II/0039; IMbrave 150 is a Phase III, open-label, multicenter, randomized, two-arm pivotal study designed to evaluate the efficacy and safety of atezolizumab + bevacizumab versus sorafenib in patients with locally advanced or metastatic hepatocellular carcinoma who had not received prior systemic treatment. In addition, the MAH took the opportunity to clarify in section 4.4 of the SmPC that the exclusion of patients with hepatitis B or hepatitis C infection only applies to non-HCC patients."	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 06.05.2021.
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0059 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "C.I.13: Submission of the final report from study MO39196 (IMpassion131), a phase III, multicenter, randomized, placebo-controlled study of Tecentriq in combination with paclitaxel in 1L metastatic triple negative breast cancer as recommended by the CHMP during procedure EMEA/H/C/004143/X/0017 The requested variation proposed no amendments to the Product Information."
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0060 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 4.2 of the SmPC in order to harmonise the atezolizumab posology regimen of 840 mg every 2 weeks, 1200 mg every 3 weeks and 1680 mg every 4 weeks administered as an IV infusion across the currently authorised indications of NSCLC, ES-SCLC, TNBC and HCC, based on PK modelling and simulation data. As a consequence of the harmonised dose schedules, the MAH is applying for a combined SmPC and PL. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include minor editorial changes to the PI."
Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/II/0091 ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4 and 4.5 of the SmPC to include information on administration of an additional dose of 50 mg dolutergravir when Triumeq is co-administered with strong enzyme inducing drugs, sections 4.4 and 4.5 to include information on co-administration of Triumeq and supplements or multivitamins containing calcium, iron or magnesium when taken with food and section 5.2 to include information on the elimination half-life of lamivudine. The Package Leaflet is updated accordingly. These changes follow the CHMP request to align the Product Information of Triumeq and Dovato, made at the time of

recommending the initial marketing authorisation of Dovato. In addition, the MAH took the opportunity to update the details of the Northern Ireland local representative in line with the QRD template v. 10.2."

TRIXEO AEROSPHERE - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide - EMEA/H/C/004983/II/0002

AstraZeneca AB, Rapporteur: Peter Kiely, "C.I.4. Update of section 5.1. of the SmPC in order to add information on the effects on all-cause mortality based on the supplement to the study PT010005 Clinical Study Report on all cause-mortality and additional data analyses to address the concerns identified during the evaluation of the MAA."

Venclyxto - venetoclax - EMEA/H/C/004106/II/0031

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, " to update venetoclax SmPC wording regarding Tumour lysis syndrome (TLS) prophylaxis and management following an update to the Company Core Data Sheet (CCDS) as result of a medical safety assessment conducted on TLS post-marketing reports. The proposed changes to the SmPC include sections 4.2 and 4.4:

• Section 4.2: A more prescriptive table which replaces the text around the risk assessment, prophylaxis and monitoring measures based on the level of tumour burden. In addition, the text on the recommended dose modifications for toxicities is replaced by a table format for clarity.

• Section 4.4: the text is revised to emphasise the fact that TLS occur in all patients and requires adequate risk assessment that considers comorbidities, particularly renal impairment, and other risk factors such as splenomegaly."

Request for Supplementary Information adopted on 25.03.2021, 25.02.2021, 12.11.2020.

Verzenios - abemaciclib - EMEA/H/C/004302/II/0016/G

Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to include OS interim results from MONARCH 3 study, a randomised, double blind,

placebo controlled phase 3 study in women with HR positive, HER2 negative locally advanced or metastatic breast cancer who had not received prior systemic therapy in this disease setting. In addition, the MAH is updating the ATC code in the SmPC. The MAH is also taking the opportunity to update the list of local representatives in the Package Leaflet in line with the QRD template 10.2."	
Vfend - voriconazole - EMEA/H/C/000387/II/0142/G Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3, 4.4 and 4.5 of the SmPC in order to add new contraindications to naloxegol and tolvaptan and add a Drug-Drug Interaction with lurasidone, include clarification text regarding adrenal insufficiency and Cushing's syndrome to the warnings and precautions for use, and re-order some of the drug-drug interaction information, respectively. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to correct an oversight from a previous procedure in the labelling (addition of the excipient sodium benzoate in section 3 of the outer and inner label for the Powder for oral suspension in line with SmPC section 2 and PL sections 2 and 6)."	
WS1990 **Combivir-EMEA/H/C/000190/WS1990/0099** **Dovato-EMEA/H/C/004909/WS1990/0018** **Epivir-EMEA/H/C/000107/WS1990/0115** **Kivexa-EMEA/H/C/000581/WS1990/0088** **Triumeq-EMEA/H/C/002754/WS1990/0087** **Trizivir-EMEA/H/C/000338/WS1990/0120** ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "Update of sections 4.2 and 5.2 of the SmPC to revise the information about use of the products in patients with renal impairment." Request for Supplementary Information adopted on 25.03.2021.	
WS1995 **Afinitor-EMEA/H/C/001038/WS1995/0069** **Votubia-EMEA/H/C/002311/WS1995/**	

0068 Novartis Europharm Limited, Lead Rapporteur: Janet Koenig, "Update of the Afinitor and Votubia SmPCs to include radiation recall syndrome as an adverse drug reaction observed in the post-marketing phase with unknown frequency (section 4.8) and a cautionary text regarding radiation therapy complications in 'Special warnings and precautions for use' (section 4.4). Corresponding changes are also made to the package leaflets. Taking the opportunity, the MAH also proposes some editorial changes to harmonise the information in Afinitor and Votubia labels in SmPC (section 4.7) 'Effects on ability to drive and use machines' and Package leaflet '.....(Afinitor/Votubia) with food and drink.' Afinitor label is further updated in compliance with the QRD template version 10.1, while Votubia label was already updated within the procedure II/061." Request for Supplementary Information adopted on 25.03.2021.	

B.5.3. CHMP-PRAC assessed procedures

Aimovig - erenumab - EMEA/H/C/004447/II/0013/G Novartis Europharm Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka, "Update of section 4.8 of the SmPC in line with revised clinical safety data. Submission of the study report from 5-year open-label study 20120178 with consequential changes to the section 4.8 and section 5.1 of the SmPC as well as an update of the EU RMP Type IA variation to the include ATC code for erenumab. The Package Leaflet is updated accordingly." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 09.04.2021, 11.02.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
CRYSVITA - burosumab - EMEA/H/C/004275/II/0021, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.2 of the SmPC in order to modify administration	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

instructions to include the option of self/carer-administration based on results from two Phase 3 interventional clinical safety and efficacy studies; study KRN23-003 in paediatric patients (final study report) and study KRN23-004 in adult patients (interim report). The Package Leaflet has been updated accordingly and a new section with instructions for use has been added at the end. In addition, the MAH took the opportunity to implement editorial changes in the SmPC, labelling and Package Leaflet. The updated RMP version 3.1 was agreed during the procedure."
Opinion adopted on 06.05.2021.
Request for Supplementary Information adopted on 11.02.2021.

Eylea - aflibercept - EMEA/H/C/002392/II/0069

Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, "This type II variation under category C.1.4 is to update the Posology section 4.2 of the Product Information for the indication DME based on results from the PAES VIOLET (Study 17613; (EMEA/H/C/002392/ANX/011); and to include study data to EU-PI section 5.1. The submission package also contains the AQUA CSR, a phase 4 study which served as run-in study for VIOLET."
Request for Supplementary Information adopted on 25.02.2021.

Lamzede - velmanase alfa - EMEA/H/C/003922/II/0018, Orphan

Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser, "Type II C.I.4
Update of sections 4.4, 4,8 and 5.1 of the SmPC in order to amend an existing warning on immunogenicity, update the summary of the safety profile, add cyanosis to the list of adverse drug reactions (ADRs) with frequency 'common', add the information that the safety profile observed in children under age 6 is consistent with what was observed in previous studies, update the pharnacodynamic properties. These proposed SmPC updates are based on the final results of rhLAMAN-08 study, which is listed as an Annex II study in the RMP, and is a 24-month multi-center, open-label phase II trial investigating the safety and efficacy of repeated velmanase alfa (recombinant human alpha-

mannosidase) treatment in paediatric patients <6 years if age with alpha-mannosidosis. The Package Leaflet is being update accordingly. The RMPv8.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with QRD template v10.1 and v10.2."	
Nplate - romiplostim - EMEA/H/C/000942/II/0079 Amgen Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of section 4.8 of the SmPC to add Anaphylactic reaction to the list of adverse drug reactions (ADRs) with frequency to be determined in the evaluation of the variation. The package leaflet has been amended accordingly." Request for Supplementary Information adopted on 06.05.2021.	Request for supplementary information adopted with a specific timetable.
OFEV - nintedanib - EMEA/H/C/003821/II/0040 Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.8 and 4.4 of the SmPC in order to add "nephrotic range proteinuria" as a new adverse drug reaction with a frequency of "uncommon" for "Idiopathic pulmonary fibrosis (IPF)" and "Other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype" and with a frequency of "not known" for "Systemic sclerosis associated interstitial lung disease (SSc-ILD)"and its relevant warning, respectively; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor corrections and editorial changes (correction of frequency category for renal failure in section 4.8 of the SmPC, correction of a typo of non-safety relevant information in section 5.1. of the SmPC and correction of typos in Annex II) in the EN PI." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 11.03.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0009/G Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "C.I.4, C.I.3, C.I.6 (non-EoI) Update of section 5.2 of the SmPC in order to	See 9.1

update pharmacokinetic information based on results from study CSR 19-514 (PK Comparability) and CSR 16-508 (Japanese Ethnicity Study) listed as a specific obligation in the Annex II. Annex II was proposed to be updated accordingly. The RMP version 2.1 has also been submitted." Request for Supplementary Information adopted on 25.03.2021, 10.12.2020, 30.04.2020.	
Pyramax - pyronaridine / artesunate - EMEA/H/W/002319/II/0023/G Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Adrien Inoubli, "Grouping of variations providing the final clinical study reports (CSR) of two completed studies: - Study SP-C-021-15: A Phase IIIb/IV cohort event monitoring study conducted in Central Africa to evaluate the safety in patients after the local registration of Pyramax (CANTAM study). This study is a category 3 Required Additional Pharmacovigilance Activity described in the RMP (MEA 013). - SP-C-026-18: A Randomized Open-Label Exploratory Study to Determine The Efficacy of Different Treatment Regimens of Pyramax (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections. This non-imposed study was conducted in the Gambia and Zambia and compared asymptomatic subjects with parasitaemia dosed according to the approved label of 3-day dosing with 2-day and 1-day dosing. There have been no new safety findings from the study but the RMP has been updated to reflect its details. As a result of the additional clinical data, corresponding changes to the Product Information (SmPC and PL) are proposed with the Grouping. RMP version 17 has also been submitted, updated to reflect the results of both above-mentioned CSRs, and converted to the new RMP integrated template format (Rev 2.0.1). " Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.	Request for supplementary information adopted with a specific timetable.
Tasigna - nilotinib - EMEA/H/C/000798/II/0109 Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine	Request for supplementary information adopted with a specific timetable.

Stark, "Update of SmPC sections 4.4, 4.8 and 5.1 based on the 5-year follow up data from the study CAMN107A2203 in paediatric patients. Annex II D has been updated to reflect the fulfillment of the obligation to conduct the post-authorisation efficacy study (PAES). The Package leaflet is updated accordingly. In addition, the Tasigna EU RMP version 24.0 has been updated to remove the corresponding additional pharmacovigilance activity and the missing information 'Long-term follow-up in pediatric patients'." Request for Supplementary Information adopted on 06.05.2021.	
TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/II/0069/G Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "C.I.4 type II variation: Update of section 4.8 of the SmPC in order to add rhinorrhoea to the list of adverse drug reactions (ADRs) with frequency unknown based on a systematic review of information from clinical and non-clinical studies, post-marketing data and scientific literature. The Package Leaflet has been updated accordingly. C.I.4 type II variation: Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 109MS303 (ENDORSE) listed as a category 3 study in the RMP. This is a dose-blind, multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with Relapsing-Remitting Multiple Sclerosis. The RMP version 11.1 has also been submitted." Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.	Request for supplementary information adopted with a specific timetable.
Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0032 Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné, "C.I.4 To update sections 4.8 and 5.1 of the SmPC following the interim data from the primary vaccination phase (stage 1) of study B1971057; this is a Phase 3, randomised, active-controlled, observer-blinded study to assess the immunogenicity, safety, and tolerability of bivalent rLP2086 when	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

administered as a 2-dose regimen and a first-in-human study to describe the immunogenicity, safety, and tolerability of a bivalent rLP2086 containing pentavalent vaccine (MenABCWY) in healthy subjects ≥10 to <26 years of age. The RMP version 5 has also been submitted. The MAH took the opportunity to implement some editorial changes in section 4.4 of the SmPC and sections 2, 3 and 6 of the Package Leaflet in order to comply with the excipients guideline for Sodium Chloride" Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 14.01.2021.	
Xeljanz - tofacitinib - EMEA/H/C/004214/II/0038 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Submission of an updated RMP version 17.1 in order to incorporate the category 3 US-based drug utilisation study A3921348 into the category 3 protocol of the US-based active surveillance study A3921347." Opinion adopted on 06.05.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Zercepac - trastuzumab - EMEA/H/C/005209/II/0008 Accord Healthcare S.L.U., Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski Request for Supplementary Information adopted on 11.03.2021.	

B.5.4. PRAC assessed procedures

PRAC Led **Adasuve - loxapine - EMEA/H/C/002400/II/0032** Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To submit the final clinical study report (CSR) for study AMDC- 204-401 EU PASS: Post-authorisation Observational Study to Evaluate the Safety of ADASUVE -Staccato loxapine for inhalation- in Agitated Persons in Routine Clinical Care. An updated RMP version 9.5 has also been submitted." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 14.01.2021.	
PRAC Led **Alecensa - alectinib - EMEA/H/C/004164/II/0033** Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova, PRAC-CHMP liaison: Ondřej Slanař, "Submission of an updated RMP version 3.1 in order to remove the safety concern of missing information - long term safety, based on a report of the cumulative safety data from the pivotal Phase III clinical trial ALEX (BO28984). In addition, the MAH has taken the opportunity to update the RMP to remove study BO40643 from the pharmacovigilance plan, following assessment in procedure EMEA/H/C/004164/II/0030." Request for Supplementary Information adopted on 06.05.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Benlysta - belimumab - EMEA/H/C/002015/II/0092** GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP version 40 in order to add an alternative pregnancy exposure study (Study 213928) as a category 3 study for the missing information on limited data in pregnant and lactating patients. The study is to evaluate pregnancy and infant outcomes for pregnancies in women with SLE exposed to belimumab. The RMP includes also completion date and effectiveness for the DHPC in relation to the important identified risk of psychiatric events including depression and suicidality." Opinion adopted on 06.05.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Conbriza - bazedoxifene - EMEA/H/C/000913/II/0054** Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Update of the Risk Management Plan (RMP) to include updated study milestones and to revise the RMP format in line with latest Good Pharmacovigilance Practices Guidance Module V, revision 2 guidelines." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 06.05.2021, 14.01.2021.	
PRAC Led **Lopinavir/Ritonavir Mylan - lopinavir / ritonavir - EMEA/H/C/004025/II/0016** Mylan S.A.S, Generic, Generic of Kaletra, Rapporteur: John Joseph Borg, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Jean-Michel Race, "Submission of an updated RMP v. 4.0 in order to implement the RMP template in accordance with GVP Module V rev. 2 and to align the safety concerns with the reference product" Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 11.03.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Mavenclad - cladribine - EMEA/H/C/004230/II/0015** Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP version 1.5 in order to align to the RMP template Rev. 2. In addition, the MAH took the opportunity to include long-term safety data from the completed PREMIERE registry and remove the completed study from the pharmacovigilance plan, update of the status of the post-approval safety studies CLARION and CLEAR and update the RMP with the most recent post-approval safety data from the PBRER." Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **OCALIVA - obeticholic acid - EMEA/H/C/004093/II/0026, Orphan** Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 1.2 in order to update the format in accordance with template to EMA/164014/2018 Rev.2.0.1 and to add Specific Obligation clinical studies 747-302 and 747-401 to the pharmacovigilance plan. This change has been agreed by the CHMP in the outcome Ocaliva 2020 Annual Renewal (EMEA/H/C/004093/R/0023). Other changes also include an update to the	Request for supplementary information adopted with a specific timetable.

exposure data from clinical studies and addition of data on post-marketing experience up to the DLP (26 May 2020) and addition of some specific relevant SmPC wording in the risk minimisation measures." Request for Supplementary Information adopted on 06.05.2021.	
PRAC Led **Ovaleap - follitropin alfa - EMEA/H/C/002608/II/0034** Theramex Ireland Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final study report for SOFIA (Safety of Ovaleap (Follitropin alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies, XM17-WH-5005) listed as a category 3 study in the RMP. This is a multi-national, comparative, prospective, non-interventional, observational cohort study. The RMP version 3.3 has also been submitted." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 14.01.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Retacrit - epoetin zeta - EMEA/H/C/000872/II/0100** Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final study report of a joint post-authorisation safety cohort study of Retacrit/Silapo (epoetin zeta) administered subcutaneously for the treatment of renal anemia (PASCO II) listed as a category 3 study in the RMP. The primary objective of the observational study was to estimate the incidence of pure red cell aplasia (PRCA), neutralising antibodies, lack of efficacy and thromboembolic events under treatment with Retacrit/Silapo (epoetin zeta). The RMP version 16 has also been submitted." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 11.03.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Revatio - sildenafil - EMEA/H/C/000638/II/0091** Upjohn EESV, Rapporteur: Johann Lodewijk	Request for supplementary information adopted with a specific timetable.

Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 7.0 in order to update the summary of safety concerns in line with GVP module V rev 2 guidelines. Consequently, the educational programme for the risk of hypotension is proposed to be terminated." Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.	
PRAC Led **RotaTeq - rotavirus vaccine (live, oral) - EMEA/H/C/000669/II/0085** MSD Vaccins, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "To update the RMP for RotaTeq to version 7.2 to meet the requirements and updated definitions in the Guideline on good pharmacovigilance practices (GVP) module V (EMA/838713/2011; Rev 2); consequently, the list of safety concerns is updated and a reclassification of important risks is proposed. In addition, the proposed RMP version 7.2 implements the removal of hypersensitivity and severe combined immunodeficiency (SCID) from the list of safety concerns as requested by the PRAC in PSUR procedure (PSUSA/00002666/201911)." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 11.02.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Silapo - epoetin zeta - EMEA/H/C/000760/II/0062** STADA Arzneimittel AG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final study report of a joint post-authorisation safety cohort study of Retacrit/Silapo (epoetin zeta) administered subcutaneously for the treatment of renal anemia (PASCO II) listed as a category 3 study in the RMP. The primary objective of the observational study was to estimate the incidence of pure red cell aplasia (PRCA), neutralising antibodies, lack of efficacy and thromboembolic events under treatment with Retacrit/Silapo (epoetin zeta). The RMP version 12 has also been submitted." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 11.03.2021.	
PRAC Led **Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0014** AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Update of sections 4.3, 4.4 and 4.8 of the SmPC, following an update to the Company Core Data Sheet in relation to thromboembolism with thrombocytopenia, to contraindicate the vaccine to patients who have experienced major venous and/or arterial thrombosis in combination with thrombocytopenia following vaccination with any COVID-19 vaccine, update the warnings on thrombocytopenia and coagulation disorders and include the frequency thrombosis with thrombocytopenia of "less than 1/100,000". The package leaflet is updated accordingly."	See 9.1
PRAC Led **WS1653** **Enbrel-EMEA/H/C/000262/WS1653/0230** **LIFMIOR (EXP)-EMEA/H/C/004167/ WS1653/0024** Pfizer Europe MA EEIG, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of the second 5-year report from the British Society for Rheumatology Biologics Register (BSRBR, also referred as study B1801309) listed as a category 3 study in the RMP. This is a prospective observational cohort study which investigates the long-term outcomes of patients with rheumatoid arthritis treated with etanercept with particular reference to safety." Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 26.11.2020, 17.04.2020, 16.01.2020.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **WS1970** **Eucreas-EMEA/H/C/000807/WS1970/ 0081** **Galvus-EMEA/H/C/000771/WS1970/0067** **Icandra-EMEA/H/C/001050/WS1970/ 0084** **Jalra-EMEA/H/C/001048/WS1970/0069** **Xiliarx-EMEA/H/C/001051/WS1970/0067**	Request for supplementary information adopted with a specific timetable.

Zomarist-EMEA/H/C/001049/WS1970/0083 Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP (version 15.0) in order to bring it in line with revision 2 of GVP module V on 'Risk management systems' and aligned with the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00003113/201802) adopted in October 2018. Annex II.D of the product information is updated to remove the statement around submission of an RMP update every 3 years." Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.	
PRAC Led **WS2013** **Abseamed-EMEA/H/C/000727/WS2013/0092** **Binocrit-EMEA/H/C/000725/WS2013/0091** **Epoetin alfa Hexal-EMEA/H/C/000726/WS2013/0091** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau, Lead PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of the RMP v.18 for Abseamed, Binocrit, Epoetin Alfa Hexal in line with the RMP of the originator product Eprex. The following changes have been introduced: · Wording of two potential risks was harmonised in line with the originator's RMP: The term "tumor growth potential" was replaced with "disease progression", and "premature death" was replaced with "survival impact". · The clinical study data on these two topics were shortened, in line with the originator's RMP. · Removal of TRIGONS study proposal (MEA18; HX575-502) as additional pharmacovigilance activity; in alignment with originator RMP, risks of disease progression and survival impact will be monitored by routine pharmacovigilance and continue to be reviewed in PSURs. · Statistical output tables were integrated into Annex 7 following a PRAC request." Request for Supplementary Information adopted on 06.05.2021.	Request for supplementary information adopted with a specific timetable.

PRAC Led **WS2040/G** **Aybintio-EMEA/H/C/005106/WS2040/0004/G** **Onbevzi-EMEA/H/C/005640/WS2040/0001/G** Samsung Bioepis NL B.V., Lead Rapporteur: Andrea Laslop, Lead PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, "C.I.11.z - To provide an updated RMP, to remove the missing information of "Long term effects of bevacizumab when used in the paediatric population" to align the safety concerns to the reference product Avastin. C.I.2.a - To update sections 4.4, 5.1 and 6.6 of the SmPC following assessment of the same change for the reference product Avastin (procedure EMEA/H/C/000582/IB/0118). In addition, the marketing authorisation holder has taken the opportunity to add the date of first authorisation in section 9 of the SmPC and align the PI with the latest QRD template (v. 10.2) for Onbevzi." Opinion adopted on 06.05.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.5. CHMP-CAT assessed procedures

Zynteglo - betibeglogene autotemcel - EMEA/H/C/003691/II/0022, Orphan, ATMP bluebird bio (Netherlands) B.V, Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik Opinion adopted on 12.05.2021. Request for Supplementary Information adopted on 16.04.2021.	

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

PRAC Led **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0044, ATMP** Amgen Europe B.V., Rapporteur: Olli Tenhunen, CHMP Coordinator: Johanna Lähteenvuo, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-	

CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study 20180099 listed as a category 3 study in the RMP. This is a cross-sectional survey to evaluate physician knowledge of safety messages included in the physician education booklet (PEB) for Imlygic."	

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2024 **Infanrix hexa-EMEA/H/C/000296/ WS2024/0296** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 29.04.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2030 **Biktarvy-EMEA/H/C/004449/WS2030/ 0037** **Descovy-EMEA/H/C/004094/WS2030/ 0053** **Genvoya-EMEA/H/C/004042/WS2030/ 0075** **Odefsey-EMEA/H/C/004156/WS2030/ 0050** Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes, "To update section 4.4 of the SmPC and section 2 of the PL with information regarding nephrotoxicity, in alignment with the outcome of procedure EMEA/H/C/PSUSA/00010575/201911 already approved for Vemlidy. In addition, the marketing authorisation holder has taken the opportunity to introduce minor editorial changes for Biktarvy and to align the PI of all four products to the latest QRD template (v. 10.2)."	
WS2033 **Hexacima-EMEA/H/C/002702/WS2033/ 0116** **Hexyon-EMEA/H/C/002796/WS2033/ 0120** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 29.04.2021.	Request for supplementary information adopted with a specific timetable.
WS2045/G	Positive Opinion adopted by consensus on

OFEV-EMEA/H/C/003821/WS2045/0043/G **Vargatef-EMEA/H/C/002569/WS2045/0040/G** Boehringer Ingelheim International GmbH, Lead Rapporteur: Peter Kiely, Opinion adopted on 29.04.2021.	29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2047 **HyQvia-EMEA/H/C/002491/WS2047/0069** **Kiovig-EMEA/H/C/000628/WS2047/0108** Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus	
WS2051/G **Entresto-EMEA/H/C/004062/WS2051/0037/G** **Neparvis-EMEA/H/C/004343/WS2051/0035/G** Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 06.05.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.9. Information on withdrawn type II variation / WS procedure

Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0003 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, "Update of section 5.1 of the SmPC in order to introduce effectiveness information of Fluad (trivalent formulation) in the product information of Fluad Tetra based on the results from three retrospective observational studies "CORE 17-18 and 18-19", "HEOR 17-18" and "HEOR 18-19") and a randomised clinical trial "LTCF 16-17".”Request for Supplementary Information adopted on 28.01.2021, 15.10.2020.	The MAH withdrew the procedure on 06.05.2021.

B.5.10. Information on type II variation / WS procedure with revised timetable

Nulojix - belatacept - EMEA/H/C/002098/II/0065/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 25.03.2021, 12.11.2020, 12.03.2020.	Request by the applicant for an extension of the clock stop to respond to the RSI adopted on 25.03.2021.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

abrocitinib - EMEA/H/C/005452
Indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
List of Questions adopted on 28.01.2021.

Akynzeo - fosnetupitant / netupitant / palonosetron - EMEA/H/C/003728/X/0031
Helsinn Birex Pharmaceuticals Limited, Rapporteur: Peter Kiely, PRAC Rapporteur: Ilaria Baldelli, "Extension application to introduce a new pharmaceutical form (concentrate for solution for infusion)."
List of Questions adopted on 28.01.2021.

artesunate - EMEA/H/C/005550, Orphan
Amivas Ireland Ltd, treatment of malaria
List of Questions adopted on 28.01.2021.

fingolimod - EMEA/H/C/005661
treatment of multiple sclerosis
List of Questions adopted on 25.03.2021.

lonapegsomatropin - EMEA/H/C/005367, Orphan
Ascendis Pharma Endocrinology Division A/S, Treatment of growth hormone deficiency
List of Questions adopted on 28.01.2021.

sodium thiosulfate - EMEA/H/C/005130, PUMA
for the prevention of ototoxicity induced by cisplatin (CIS) chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumours.
List of Questions adopted on 25.06.2020.

pegcetacoplan - EMEA/H/C/005553, Orphan

Apellis Ireland Limited, paroxysmal nocturnal haemoglobinuria (PNH)
List of Questions adopted on 28.01.2021.

ripretinib - EMEA/H/C/005614, Orphan
Deciphera Pharmaceuticals (Netherlands) B.V., Treatment of patients with advanced gastrointestinal stromal tumour (GIST)
List of Questions adopted on 28.01.2021.

glucarpidase - EMEA/H/C/005467, Orphan
Protherics Medicines Development Europe B.V., treatment of patients at risk of methotrexate toxicity
List of Questions adopted on 10.12.2020.

B.6.4. Annual Re-assessments: timetables for adoption

Chenodeoxycholic acid Leadiant - chenodeoxycholic acid - EMEA/H/C/004061/S/0017, Orphan
Leadiant GmbH, Rapporteur: Konstantinos Markopoulos, PRAC Rapporteur: Adam Przybylkowski

Elaprase - idursulfase - EMEA/H/C/000700/S/0092
Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Firdapse - amifampridine - EMEA/H/C/001032/S/0071
SERB SA, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Adakveo - crizanlizumab - EMEA/H/C/004874/R/0003, Orphan
Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Laurence de Fays

Cystadrops - mercaptamine - EMEA/H/C/003769/R/0022, Orphan
Recordati Rare Diseases, Rapporteur: Kristina Dunder, Co-Rapporteur: Maria Concepcion

Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/R/0022
sanofi-aventis groupe, Rapporteur: Kristina Dunder, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Menno van der Elst

Talmanco - tadalafil - EMEA/H/C/004297/R/0011
Mylan S.A.S, Generic, Generic of Adcirca, Cialis, Rapporteur: Tomas Radimersky, PRAC Rapporteur: Maria del Pilar Rayon

Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/R/0035
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Ilaria Baldelli

Vihuma - simoctocog alfa - EMEA/H/C/004459/R/0026
Octapharma AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga

Zinplava - bezlotoxumab - EMEA/H/C/004136/R/0029
Merck Sharp & Dohme B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Adam Przybylkowski

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMEA/H/C/001206/II/0074
GlaxoSmithkline Biologicals SA, Informed Consent of Pandemrix (EXP), Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include use in children from 6 months to <18 years for Adjupanrix based on the results of the studies: study H5N1-013, a phase II, non-randomized, open-label study to evaluate the safety and immunogenicity in children aged 6 to 35 months and study H5N1-032, a phase III, randomized, open, active-controlled study to

evaluate the safety and immunogenicity in children aged 3 to 17 years. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 6.6 of the SmPC are updated and the Package Leaflet is updated in accordance. Further, the MAH proposed to update section 4.4 with information on sodium and potassium content in line with the excipients guideline, as well as to add wording on traceability. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2, the MAH performed minor editorial changes and removed information related to the withdrawn Prepandrix marketing authorisation. Version 13 of the RMP has also been submitted."	
Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0129 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication for Hizentra in order to expand the approved secondary immunodeficiencies (SID) indications in the Hizentra SmPC to any symptomatic SID in accordance with the Guideline on core SmPC for human normal immunoglobulin for intravenous administration (EMA/CHMP/BPWP/94038/ 2007 Rev 5; CHMP, 2018); as a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.6 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."	
Jakavi - ruxolitinib - EMEA/H/C/002464/II/0053 Novartis Europharm Limited, Rapporteur: Filip Josephson, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Annika Folin, "Extension of indication to include treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies for Jakavi; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted. In addition, the Marketing	

authorisation holder (MAH) took the opportunity to update the list of local representative for The Netherlands in the Package Leaflet."

Kalydeco - ivacaftor - EMEA/H/C/002494/II/0096, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, "Extension of indication for Kalydeco tablets in combination regiment with Kaftrio to include the treatment of adults, adolescents and children aged 6 years and older with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene or heterozygous for F508del and have a minimal function (MF) mutation in the CFTR gene. This application is based on the results of study VX18-445-106, a phase 3, open-label, multicentre study in subjects 6 through 11 years of age, with F/MF and F/F genotypes. As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The Packaged Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted."

Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G

Karyopharm Europe GmbH, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, "Group of variations including an extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and a quality variation for the addition of a new pack size to align with the dose modification guidance for the new indication. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size. Annex II is updated to reflect the completion of the Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 1.1) is amended consequently."

Olumiant - baricitinib - EMEA/H/C/004085/II/0028

Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Adam Przybylkowski, "C.I.6 - Extension of indication to include

treatment of coronavirus disease 2019 (COVID 19) in hospitalised adult and paediatric patients aged 10 years and older who require low-flow oxygen or non invasive ventilation/high flow oxygen for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. Version 11.1 of the RMP has also been submitted."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Rapiscan - regadenoson - EMEA/H/C/001176/II/0038
GE Healthcare AS, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Jayne Crowe, "Modification of existing indication to allow use in line with new imaging technologies that have evolved since initial approval of Rapiscan; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance."

Skyrizi - risankizumab - EMEA/H/C/004759/II/0014
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Peter Kiely, PRAC Rapporteur: Liana Gross-Martirosyan, "Ext of indication for the treatment of active psoriatic arthritis in adults. Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 to the SmPC have been updated. The Package leaflet is updated accordingly. Additionally, Annex II is also updated."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Briviact - brivaracetam - EMEA/H/C/003898/II/0034/G
UCB Pharma S.A., Rapporteur: Filip Josephson

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0028/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson
Opinion adopted on 07.05.2021.

COMIRNATY - COVID-19 mRNA vaccine

(nucleoside-modified) -
EMEA/H/C/005735/II/0033/G
BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson

COVID-19 Vaccine Moderna - COVID-19
mRNA vaccine (nucleoside-modified) -
EMEA/H/C/005791/II/0013/G
Moderna Biotech Spain, S.L., Rapporteur: Jan
Mueller-Berghaus

Cyramza - ramucirumab -
EMEA/H/C/002829/II/0041
Eli Lilly Nederland B.V., Rapporteur: Paula
Boudewina van Hennik

Kaftrio - ivacaftor / tezacaftor /
elexacaftor -
EMEA/H/C/005269/II/0011/G, Orphan
Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Johann Lodewijk Hillege

Kineret - anakinra -
EMEA/H/C/000363/II/0083
Swedish Orphan Biovitrum AB (publ),
Rapporteur: Kirstine Moll Harboe

Lonquex - lipegfilgrastim -
EMEA/H/C/002556/II/0064/G
Teva B.V., Rapporteur: Outi Mäki-Ikola

MabThera - rituximab -
EMEA/H/C/000165/II/0185/G
Roche Registration GmbH, Rapporteur: Sinan B.
Sarac

Menveo - Meningococcal group A, C, W135
and Y conjugate vaccine -
EMEA/H/C/001095/II/0101
GSK Vaccines S.r.l, Rapporteur: Johann
Lodewijk Hillege

Nucala - mepolizumab -
EMEA/H/C/003860/II/0043
GlaxoSmithKline Trading Services Limited,
Rapporteur: Peter Kiely

Nyvepria - pegfilgrastim -
EMEA/H/C/005085/II/0002/G
Pfizer Europe MA EEIG, Rapporteur: Ondřej
Slanař

Ondexxya - andexanet alfa -
EMEA/H/C/004108/II/0020/G
Alexion Europe SAS, Rapporteur: Jan Mueller-

Berghaus

OPDIVO - nivolumab -
EMEA/H/C/003985/II/0103
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa

Pemetrexed Sandoz - pemetrexed -
EMEA/H/C/004011/II/0011/G
Sandoz GmbH, Generic, Generic of Alimta, Rapporteur: Bjorg Bolstad

SCENESSE - afamelanotide -
EMEA/H/C/002548/II/0037, Orphan
Clinuvel Europe Limited, Rapporteur: Janet Koenig

TAKHZYRO - lanadelumab -
EMEA/H/C/004806/II/0021/G, Orphan
Shire Pharmaceuticals Ireland Limited, Rapporteur: Kristina Dunder

Tremfya - guselkumab -
EMEA/H/C/004271/II/0029/G
Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics

Ultomiris - ravulizumab -
EMEA/H/C/004954/II/0015/G
Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -
EMEA/H/C/005675/II/0016
AstraZeneca AB, Rapporteur: Sol Ruiz
Request for Supplementary Information adopted on 12.05.2021.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -
EMEA/H/C/005675/II/0018
AstraZeneca AB, Rapporteur: Sol Ruiz
Opinion adopted on 12.05.2021.

YUFLYMA - adalimumab -
EMEA/H/C/005188/II/0002
Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola

Ziextenzo - pegfilgrastim -
EMEA/H/C/004802/II/0014
Sandoz GmbH, Rapporteur: Andrea Laslop

Zubsolv - buprenorphine / naloxone -
EMEA/H/C/004407/II/0015

Accord Healthcare S.L.U., Rapporteur: Peter Kiely

WS1964
HyQvia-EMEA/H/C/002491/WS1964/0072
Kiovig-EMEA/H/C/000628/WS1964/0110
Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2026
AMGEVITA-EMEA/H/C/004212/WS2026/0026
Aranesp-EMEA/H/C/000332/WS2026/0155
MVASI-EMEA/H/C/004728/WS2026/0021
Prolia-EMEA/H/C/001120/WS2026/0089
Repatha-EMEA/H/C/003766/WS2026/0052
XGEVA-EMEA/H/C/002173/WS2026/0077
Amgen Europe B.V., Lead Rapporteur: Martina Weise

WS2037
Gardasil-EMEA/H/C/000703/WS2037/0092
Gardasil 9-EMEA/H/C/003852/WS2037/0045
MSD Vaccins, Lead Rapporteur: Kristina Dunder

WS2044
Herceptin-EMEA/H/C/000278/WS2044/0171
MabThera-EMEA/H/C/000165/WS2044/0184
Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2074
Riarify-EMEA/H/C/004836/WS2074/0012
Trimbow-EMEA/H/C/004257/WS2074/0017
Trydonis-EMEA/H/C/004702/WS2074/0012
Chiesi Farmaceutici S.p.A., Lead Rapporteur: Janet Koenig

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0089, Orphan
Takeda Pharma A/S, Rapporteur: Paula

Boudewina van Hennik, "Submission of long term follow-up data for clinical trial Echelon-2 (SGN035-014): A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphoma. The study is submitted to fulfil the post-approval-measure MEA 015.1."

Calquence - acalabrutinib - EMEA/H/C/005299/II/0005

AstraZeneca AB, Rapporteur: Filip Josephson, "Submission of the final report from study XS-1468 to further characterise the plasma protein binding of acalabrutinib and its metabolite ACP-5862 in different species."

Cosentyx - secukinumab - EMEA/H/C/003729/II/0073

Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, "C.I.4 - Update of section 5.1 of the SmPC in order to include the 52 weeks results from study A2311; a multicenter, randomized, open-label study in paediatric patients aged 6 years to less than 18 years with moderate to severe chronic plaque psoriasis."

Dupixent - dupilumab - EMEA/H/C/004390/II/0046

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, "Update of section 4.8 of the SmPC to introduce a new ADR (facial rash) with uncommon frequency. The package leaflet will be updated accordingly."

Erleada - apalutamide - EMEA/H/C/004452/II/0015

Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.1 of the SmPC in order to update the efficacy, safety information based on final results from study 56021927PCR3002 (TITAN) listed as Letter of Recommendations (11 December 2019, EMEA/H/C/004452/II/0001); this is a double-blind, placebo-controlled, multinational, multicenter Phase 3 study in metastatic metastatic castration-sensitive prostate cancer (mCSPC) patients."

Fasenra - benralizumab - EMEA/H/C/004433/II/0036

AstraZeneca AB, Rapporteur: Fátima Ventura, PRAC Rapporteur: David Olsen, "Update of RMP to remove long-term use of benralizumab, serious hypersensibility, loss of/reduction of long-term efficacy as safety concern and to change categorisation of helminth infection from important identified risk to important potential risk.
RMP version 4.0 is submitted"

Imfinzi - durvalumab - EMEA/H/C/004771/II/0030/G

AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Update of sections 4.2. and 4.4 the SmPC in order to change posology recommendations for management of immune-mediated adverse reactions and amend an existing warning on Immune-mediated type 1 diabetes mellitus to include diabetic ketoacidosis; these changes are based on case studies reports, updated guidelines.
The Package Leaflet is updated accordingly.
In addition, the MAH took the opportunity to make some minor corrections to section 4.8 of the SmPC."

Revestive - teduglutide - EMEA/H/C/002345/II/0053, Orphan

Shire Pharmaceuticals Ireland Limited, Rapporteur: Kirstine Moll Harboe, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the Product information with results from two studies included in the paediatric investigation plan (PIP). Study SHP633-1 was performed to evaluate the safety, efficacy/pharmacodynamics (PD), and pharmacokinetics (PK) of teduglutide in infants 4 to 12 months gestational age with SBS and who are dependent on parenteral support. The second study is a paediatric population PK model including data from study SHP633-301.
The Package Leaflet was updated accordingly.
In addition, the MAH took the opportunity to make editorial changes to section 4.5 of the SmPC."

SIRTURO - bedaquiline - EMEA/H/C/002614/II/0043, Orphan

Janssen-Cilag International NV, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC to include reference on the use of bedaquiline as specified in the product

information of other medicines used for the treatment of pulmonary tuberculosis (TB) caused by multidrug-resistant Mycobacterium tuberculosis (MDR-TB), based on recent information regarding EU approval of pretomanid, as part of a combination regimen with bedaquiline and linezolid. In addition, the MAH took the opportunity to include an editorial correction in section 5.1 of the SmPC and to update the contact details for the local representative for UK in the package leaflet, in line with QRD version 10.2."

Tecentriq - atezolizumab - EMEA/H/C/004143/II/0061

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Submission of an updated RMP version 20.0 in order to add severe cutaneous adverse reactions (SCARs) as an important identified risk and its associated risk minimisation measures, a DHPC, following the addition of SCARS to the Tecentriq PI with procedure EMEA/H/C/004143/II/0054. In addition, the MAH has also taken the opportunity to update the due dates of final CSR of two Post-authorisation efficacy studies."

Tysabri - natalizumab - EMEA/H/C/000603/II/0127

Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, "Update of section 4.6 of the SmPC in order to update information on pregnancy following a safety signal assessment of cases of neonatal thrombocytopenia that may be associated with natalizumab treatment."

Vazkepa - icosapent ethyl - EMEA/H/C/005398/II/0001

Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise, "C.I.13: Submission of the final report from study assessing the in vitro effects of Eicosapentaenoic acid (EPA) on Cloned hERG Potassium Channels Expressed in Human Embryonic Kidney Cells."

Vfend - voriconazole - EMEA/H/C/000387/II/0143

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alexandre Moreau, "Update of sections 4.4 and 4.5 of the SmPC in order to add a new warning on co-administration with glasdegib and add drug-

drug interaction information with eszopiclone, glasdegib, tretinoin and tyrosine kinase inhibitors metabolised by CYP3A4; the Package Leaflet is updated accordingly."

Viramune - nevirapine - EMEA/H/C/000183/II/0147

Boehringer Ingelheim International GmbH, Rapporteur: Bruno Sepodes, Co-Rapporteur: Christophe Focke, "Update of sections 4.4 and 5.2 of the SmPC in order to remove wording on precautionary measures related to reassuring that tablet remnants in faeces have no impact on the therapeutic response of Viramune, based on additional clinical and pharmacovigilance data that have become available; the Package Leaflet is updated accordingly.
In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.2."

Viread - tenofovir disoproxil - EMEA/H/C/000419/II/0204

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Adrien Inoubli, "Submission of final study report for study GS-US-174-0144, listed as category 3 study in the RMP for Viread. This is a randomized, double-blind evaluation of the antiviral efficacy, safety and tolerability of Tenofovir disporoxil fumarate. This application fulfils the Article 46 commitment to provide the final Week 192 study results for clinical measure 'Study 5' (Study GS_US_174-0144) listed in the PIP. Section 5.1 of the SmPC is being amended accordingly. Additionally, the risk minimisation measures for paediatrics are being removed from the RMP and Annex II of the PI. The Package Leaflet has been updated accordingly. The MAH took the opportunity to implement minor linguistic amendments throughout the PI. In addition, the expression of lactose content in Annex I for the tablets was changed, to refer to lactose base (not as monohydrate), in line with current practice. The RMP version 25.1 has been submitted."

Yondelis - trabectedin - EMEA/H/C/000773/II/0063

Pharma Mar, S.A., Rapporteur: Sinan B. Sarac,

"Update of section 4.8 of the SmPC in order to revise the frequency of ADRs based on a pooled safety analysis. the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2 Rev. 1"	
Zavesca - miglustat - EMEA/H/C/000435/II/0072/G Janssen-Cilag International N.V., Rapporteur: Kristina Dunder, "Update of sections 4.4, 4.6 and 5.3 of the SmPC in order to improve clarity and to implement linguistic changes following an update of the non-clinical information in the MAH's Company Core Data Sheet. In addition, the MAH took the opportunity to make editorial changes in the Annexes, and to update the list of local representatives in the Package Leaflet. The application also includes a type IA variation . Annex II is updated accordingly."	
WS2048 **Kalydeco-EMEA/H/C/002494/WS2048/0101** **Symkevi-EMEA/H/C/004682/WS2048/0030** Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Rhea Fitzgerald, "Update of the Product information to provide the final clinical study report (CSR) Part A of Study VX17- 661-116 (A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation). Consequently, the SmPC sections 4.2, 4.5, 4.8 and 5.1 and the package leaflet are updated accordingly. The RMP is also updated."	
WS2083/G **Nilemdo-EMEA/H/C/004958/WS2083/0013/G** **Nustendi-EMEA/H/C/004959/WS2083/0014/G** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "C.I.13: Submission of the final reports of non-clinical (in vitro) studies evaluating drug interactions of bempedoic acid	

with substrates of OAT2 (MEA 004.2, MEA 005.1 and MEA 006.2) ."

WS2085
Kaftrio-EMEA/H/C/005269/WS2085/0014
Kalydeco-EMEA/H/C/002494/WS2085/0099
Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Martin Huber, "Update of SmPC sections 4.4 and 4.8 following cases of liver failure in the post marketing setting. The PL is updated accordingly. The RMP version 3.1 is submitted for Kaftrio."

B.6.10. CHMP-PRAC assessed procedures

Adenuric - febuxostat -
EMEA/H/C/000777/II/0061
Menarini International Operations Luxembourg S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser, "C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study FAST (Febuxostat versus Allopurinol Streamlined Trial) listed as a category 3 study in the RMP; this is an interventional study investigating the cardiovascular safety of febuxostat in comparison with allopurinol in patients with chronic symptomatic hyperuricaemia. The Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to update the warning relevant to the content of sodium according to the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use'."

Cometriq - cabozantinib -
EMEA/H/C/002640/II/0044, Orphan
Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "Update of the annex IIE and SmPC section 5.1 to remove the specific obligation (SOB 001) and the reference to the conditional approval based on the final results from the study XL184-401 (EXAMINER), a randomised, double-blind

study to evaluate the efficacy and safety of cabozantinib (XL184) at 60 mg/day compared to a 140 mg/day in progressive, metastatic medullary thyroid cancer patients. The package leaflet is updated accordingly. The updated RMP version 5.4 has also been submitted.
With this submission, the MAH is proposing to revert from conditional marketing authorisation to full marketing authorisation.
Additionally, the MAH took the opportunity to bring the Product Information in line with the latest QRD template version 10.2 Rev 1, to add the sodium content in the Summary of Product Characteristics and Package Information Leaflet in line with the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' and update details of local representatives."

Cosentyx - secukinumab - EMEA/H/C/003729/II/0076

Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia, "C.I.4 - Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen for adult plaque psoriasis patients and psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis based on the final results from study CAIN457A2324 and exposure-response modelling; this is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted."

Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0044/G, Orphan

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Annika Folin, "C.I.4 Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include the administration of obinutuzumab as a short duration infusion (SDI) of approximately 90 minutes in patients with Follicular Lymphoma (FL), based on the end of induction safety and efficacy data from the ongoing Phase IV study MO40597 (GAZELLE); the Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In

addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.
C.I.11.z
Update of RMP version 8.0 to:
- change the due date for the submission of the final CSR for Category 3 study BO21223 (GALLIUM);
- remove important identified risks as per the PRAC Assessment Report for the PSUR covering period 01Nov2018 to 30Oct2019 (Procedure no. EMEA/H/C/PSUSA/00010279/201910);
- correction of clinical cut-off dates and trial exposure data from previously conducted studies"

Kisplyx - lenvatinib - EMEA/H/C/004224/II/0048

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen, "Submission of the final report from study E7080-G000-211 listed as a category 3 study in the RMP. This is a Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in subjects with 131 I-Refractory Differentiated Thyroid Cancer to evaluate whether an oral starting dose of 18 mg daily will provide comparable efficacy to a 24 mg starting dose, but have a better safety profile. The RMP version 12.3 has also been submitted."

Lenvima - lenvatinib - EMEA/H/C/003727/II/0045

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Annika Folin, "Update of the SmPC section 5.1 with additional efficacy and safety data from the Phase 2 multicentre, randomized, double-blind, non-inferiority trial in Subjects with 131I-Refractory Differentiated Thyroid Cancer to evaluate whether an oral starting dose of 18 mg daily will provide comparable efficacy to a 24 mg starting dose with an improved safety profile (study E7080-G000-211). The RMP version 12.3 is updated accordingly to remove the commitment, MEA 005.5. In addition, the MAH took the opportunity to update the details of local representatives of Bulgaria, Croatia, Estonia, Hungary, Lithuania, Latvia, Malta, Poland, Romania, Slovenia."

Natpar - parathyroid hormone -

EMEA/H/C/003861/II/0029, Orphan
Shire Pharmaceuticals Ireland Limited, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald, "Submission of the final results of study SHP634-101: An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once-Daily and Twice-Daily Dose Regimens of recombinant human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects with Hypoparathyroidism. Further clinical evaluation of an alternative dosing regimen is no longer warranted, as outlined in the current specific obligation (study SHP634-403). The conditional marketing authorisation can therefore be converted into a standard marketing authorisation (no longer subject to a specific obligation) valid for 5 years."

REKAMBYS - rilpivirine - EMEA/H/C/005060/II/0004
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of section 4.2 (to change posology recommendations) and sections 4.8, 5.1 and 5.2 of the SmPC (to update safety and efficacy information) based on week 124 results from the FLAIR study. This is a Phase III, randomized, open-label study to evaluate the efficacy, safety and tolerability of the combined treatment Cabotegravir and Rilpivirine. The Package Leaflet has been updated accordingly. Editorial changes and corrections have been carried out throughout the PI. The RMP version 3.1 has also been submitted."

Rydapt - midostaurin - EMEA/H/C/004095/II/0018/G, Orphan
Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "A.6 - Administrative change - Change in ATC Code/ATC Vet Code
C.I.4, Update SmPC in section 4.5 in order to add drug-drug interaction information with P-gp, BCRP, CYP2D6, substrates (digoxin, rosuvastatin, and dextromethorphan), based on final results from study CPKC412A2121, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section

5.2 of the SmPC and the Package Leaflet is updated accordingly. (MEA 005.3) C.I.4, Update SmPC in section 4.5 in order to add drug-drug interaction information with CYP2B6, CYP2C8, CYP3A4 substrates, based on final results from study CPKC412A2122, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section 5.2 of the SmPC and the Package Leaflet is updated accordingly. (MEA 007.2) C.I.4 Update SmPC in section 4.5 in order to add drug-drug interaction information with oral contraceptives, and section 4.6 to update information on pregnancy and contraception based on final results from study CPKC412A2123, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; the Package Leaflet is updated accordingly. (MEA 008.2) C.I.4 Update SmPC in section 5.2 in order to update pharmacokinetic information on OATP1B1 transporters based on final results from PBPK modelling study DMPK R2000528 listed as category 3 studies in the RMP (MEA 009); C.I.4 Update SmPC in section 4.2 in order to amend posology instructions, section 4.4 to amend an existing warning and section 5.2 to update pharmacokinetic information for patients with severe hepatic impairment, based on final results from study CPKC412A2116 listed as category 3 study in the RMP. This is an open label, multiple dose study to evaluate the PK of midostaurin in subjects with mild, moderate and severe hepatic impairment compared to matched healthy subjects; (MEA010) The RMP version 6.0 has also been submitted. In addition, MAH takes this opportunity to introduce minor changes to edit the wording related to the ethanol excipient in the Package Leaflet, according the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668), by rounding the volume of alcohol to the next integer number, i.e. from 16.9 to 17 ml."	
Ultomiris - ravulizumab - EMEA/H/C/004954/II/0016 Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola, "to	

update section 4.4 Special warnings and precautions for use and section 4.8 Undesirable effects of the SmPC, with consequential updates to sections 2 and 4 of the Patient Information Leaflet regarding anaphylactic reaction, hypersensitivity, and infusion-related reactions."

Vocabria - cabotegravir - EMEA/H/C/004976/II/0004

ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Update of section 4.2 (to change posology recommendations) and sections 4.4, 4.8, 5.1 and 5.2 of the SmPC (to update safety and efficacy information) based on week 124 results from the FLAIR study. This is a Phase III, randomized, open-label study to evaluate the efficacy, safety and tolerability of the combined treatment Cabotegravir and Rilpivirine. The Package Leaflet has been updated accordingly. Editorial changes and corrections have been carried out throughout the PI. The RMP version 2 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet to bring the PI in line with the latest QRD template version 10.2."

B.6.11. PRAC assessed procedures

PRAC Led

Abilify Maintena - aripiprazole - EMEA/H/C/002755/II/0040

Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study 15893N listed as a category 3 study in the RMP, requested by PRAC (EMA/PRAC/209497/2014, dated from 10 April 2014, EMEA/H/C/MEA/002). This is a non-interventional post-authorisation safety study (PASS) related to extrapyramidal symptoms: cohort study with a 2-year follow-up using European longitudinal electronic medical records or claims databases."

PRAC Led

Azarga - brinzolamide / timolol -

EMEA/H/C/000960/II/0045
Novartis Europharm Limited, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Kirstine Moll Harboe, "Update to the current Risk management plan (Version 3.0) to remove important identified risks (Respiratory disorders, Cardiovascular disorders, Corneal decompensation and Metabolic acidosis), Important potential risk (Long-term use of preserved eye drops) and Missing information (Use in paediatric patients)"

PRAC Led
Cresemba - isavuconazole - EMEA/H/C/002734/II/0035/G, Orphan
Basilea Pharmaceutica Deutschland GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Grouping of variations to
- submit the final report from study (WSA-REG-001) listed as a category 3 study in the RMP. This is a retrospective case-collection study, in which cases of invasive mucormycosis treated with isavuconazole were compared to cases treated with other systemic antifungals. The RMP version 8.2 has also been submitted.
- remove Japanese study AK1820-301 as a category 3 study from the Cresemba RMP."

PRAC Led
Duavive - estrogens conjugated / bazedoxifene - EMEA/H/C/002314/II/0030
Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study B2311060 listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation safety study of conjugated estrogens/bazedoxifene (CE/BZA) in the US, with the aim to monitor the safety profile of Duavee (CE/BZA) in comparison to estrogen and progestin combination hormone therapy (E+P HT)."

PRAC Led
Fampyra - fampridine - EMEA/H/C/002097/II/0049
Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana

Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Following a PSUR 10 assessment, update to the section 4.8 of SmPC to include new symptoms of trigeminal neuralgia. The package leaflet to be updated accordingly. The Marketing authorisation holder (MAH) introduced further editorial updates including bringing SmPC template to version 10.2 and updating contact details of the local representatives."	
PRAC Led **Gilenya - fingolimod - EMEA/H/C/002202/II/0070/G** Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the non-interventional final study report D2403 (long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with multiple sclerosis newly started on fingolimod once daily or treated with another approved disease-modifying therapy). Submission of the non-interventional final study report D2406/D2409 (long-term, prospective, non-interventional, multinational, parallel-cohort study monitoring safety in patients with MS newly initiated on fingolimod once daily or treated with another approved disease-modifying therapy (including cardiac sub-study D2409)). Consequently, the Annex IID is updated to remove the obligation to perform the PASS D2409. The RMP v 19.0 has been submitted accordingly. In addition, the MAH took the opportunity to implement some minor editorial changes."	
PRAC Led **Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0015** AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Submission of an updated RMP version 3.1 in order to update the safety concerns to add 'Thrombosis in combination with thrombocytopenia' as an important identified risk and 'Thrombosis' as an important potential risk, with consequential changes in the RMP. Updates to the Pharmacovigilance Plan have also been	See 9.1

implemented. These changes were requested by PRAC in the outcome of Signal Assessment Procedure on Embolic and Thrombotic Events with Vaxzevria EPITT no: 196833. The MAH has taken the opportunity to further update the RMP to reclassify "anaphylaxis" as an important identified risk, already reflected in the product information as an adverse reaction."	
PRAC Led **WS2086** **Epclusa-EMEA/H/C/004210/WS2086/0059** **Harvoni-EMEA/H/C/003850/WS2086/0097** **Sovaldi-EMEA/H/C/002798/WS2086/0071** Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "To provide an updated Annex II to revise the study milestone , for the hepatocellular carcinoma (HCC) recurrence post authorisation safety study (PASS) following PRAC recommendation received on 11 June 2020 (EMA procedure no.: EMEA/H/C/PSA/J/0055) for the approval of protocol amendment 1 (version 4.2). In addition, the marketing authorisation holder has taken the opportunity to update the list of local representatives and align the PI to the latest QRD template (v. 10.2)."	

B.6.12. CHMP-CAT assessed procedures

Zynteglo - betibeglogene autotemcel - EMEA/H/C/003691/II/0025, Orphan, ATMP bluebird bio (Netherlands) B.V, Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik	

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2053
Infanrix hexa-EMEA/H/C/000296/WS2053/0300
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2072
Abseamed-EMEA/H/C/000727/WS2072/0094
Binocrit-EMEA/H/C/000725/WS2072/0093
Epoetin alfa Hexal-EMEA/H/C/000726/WS2072/0093
Sandoz GmbH, Lead Rapporteur: Alexandre Moreau

WS2075
Riarify-EMEA/H/C/004836/WS2075/0014
Trimbow-EMEA/H/C/004257/WS2075/0019
Trydonis-EMEA/H/C/004702/WS2075/0014
Chiesi Farmaceutici S.p.A., Lead Rapporteur: Janet Koenig

WS2079/G
Fluenz Tetra-EMEA/H/C/002617/WS2079/0108/G
Pandemic influenza vaccine H5N1 AstraZeneca-EMEA/H/C/003963/WS2079/0041/G
AstraZeneca AB, Lead Rapporteur: Christophe Focke

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended

F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 17-20 May 2021 CHMP plenary:

G.2.2. List of procedures starting in May 2021 for June 2021 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address